BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Adrenal masses in the cancer patient: surveillance or excision.

An increasing number of patients with a history of solid organ malignancy now undergo surveillance imaging as part of their follow-up or for evaluation of other conditions.

This imaging has led to both greater identification of asymptomatic adrenal masses and subsequent confusion among clinicians regarding the evaluation and treatment.

In this review, we explore methods of biochemical testing in such patients and discuss the role of imaging techniques in their ability to differentiate benign versus malignant lesions.

[MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / therapy. Neoplasms / pathology

Genetic Alliance. consumer health - Adrenal Cancer.

MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17296812.001).

[ISSN] 1083-7159

[Journal-full-title] The oncologist

[ISO-abbreviation] Oncologist

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents

[Number-of-references] 48

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

More recently it was shown that the same light stimulus induces immediate changes in clock gene expression in the pineal and adrenal, suggesting a role of peripheral clocks in the organ-specific output.

[MeSH-minor] Adrenal Glands / metabolism. Adrenal Glands / radiation effects. Animals. Autonomic Denervation. Circadian Rhythm / genetics. Circadian Rhythm / radiation effects. Hormones / metabolism. Male. Pineal Gland / metabolism. Pineal Gland / radiation effects. Rats. Rats, Wistar

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Science. 2006 Jun 16;312(5780):1656-9 [16778057.001]

[Cites] J Biol Rhythms. 2006 Oct;21(5):350-61 [16998155.001]

[Cites] Genes Cells. 2006 Oct;11(10):1173-82 [16999737.001]

[Cites] J Neurosci. 2007 Apr 18;27(16):4359-65 [17442820.001]

[Cites] Eur J Neurosci. 2007 Nov;26(10):2731-8 [17973924.001]

[Cites] Am J Physiol Endocrinol Metab. 2008 Mar;294(3):E513-20 [18182466.001]

[Cites] Endocrinology. 2008 Apr;149(4):1914-25 [18162516.001]

[Cites] Circ Res. 2001 Jun 8;88(11):1142-50 [11397780.001]

[Cites] Am J Physiol Regul Integr Comp Physiol. 2001 Sep;281(3):R683-98 [11506981.001]

[Cites] Diabetes Metab Res Rev. 2001 Jul-Aug;17(4):250-72 [11544610.001]

[Cites] Am J Physiol Regul Integr Comp Physiol. 2002 Feb;282(2):R358-65 [11792644.001]

[Cites] Neurosci Lett. 1996 Jan 5;202(3):185-8 [8848262.001]

[Cites] Prog Brain Res. 1996;111:253-72 [8990920.001]

[Cites] J Biol Rhythms. 1998 Apr;13(2):100-12 [9554572.001]

[Cites] Biol Cell. 1997 Nov;89(8):487-94 [9618898.001]

[Cites] Eur J Neurosci. 1998 Jan;10(1):128-45 [9753120.001]

[Cites] J Neurosci. 1998 Nov 1;18(21):9078-87 [9787011.001]

[Cites] Endocrinology. 1999 Jan;140(1):207-18 [9886827.001]

[Cites] Prog Brain Res. 1998;119:365-82 [10074800.001]

[Cites] J Comp Neurol. 1999 Apr 5;406(2):171-82 [10096604.001]

[Cites] Eur J Neurosci. 1999 May;11(5):1535-44 [10215906.001]

[Cites] Neuroscience. 1999;91(2):453-61 [10366002.001]

[Cites] J Comp Physiol A. 1999 Apr;184(4):439-48 [10377978.001]

[Cites] J Mol Cell Cardiol. 2002 Feb;34(2):223-31 [11851361.001]

[Cites] J Biol Chem. 2002 Nov 15;277(46):44244-51 [12213820.001]

[Cites] Eur J Neurosci. 2003 Jan;17(2):221-8 [12542658.001]

[Cites] Genomics. 2003 May;81(5):504-9 [12706108.001]

[Cites] J Comp Neurol. 2003 Sep 8;464(1):36-48 [12866127.001]

[Cites] Diabetes. 2003 Sep;52(9):2321-30 [12941772.001]

[Cites] J Biol Chem. 2003 Oct 17;278(42):41519-27 [12865428.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):16089-94 [14657355.001]

[Cites] Am J Physiol Regul Integr Comp Physiol. 2008 Jul;295(1):R355-60 [18434440.001]

[Cites] PLoS One. 2008;3(9):e3194 [18791643.001]

[Cites] Neuroendocrinology. 2008;88(4):246-55 [18562786.001]

[Cites] Science. 2000 Apr 28;288(5466):682-5 [10784453.001]

[Cites] Brain Res. 2000 Sep 8;876(1-2):10-6 [10973587.001]

[Cites] Eur J Neurosci. 2000 Sep;12(9):3146-54 [10998098.001]

[Cites] Exp Clin Endocrinol Diabetes. 2000;108(6):389-95 [11026751.001]

[Cites] Curr Biol. 2000 Oct 19;10(20):1291-4 [11069111.001]

[Cites] Genes Dev. 2000 Dec 1;14(23):2950-61 [11114885.001]

[Cites] Annu Rev Physiol. 2001;63:647-76 [11181971.001]

[Cites] Am J Physiol Heart Circ Physiol. 2001 Mar;280(3):H1391-9 [11179089.001]

[Cites] Eur J Neurosci. 2004 Jan;19(2):318-24 [14725626.001]

[Cites] Brain Res Mol Brain Res. 2004 Jan 5;120(2):164-72 [14741406.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5339-46 [14963227.001]

[Cites] Liver Int. 2004 Jun;24(3):179-86 [15189266.001]

[Cites] Nature. 2004 Jul 22;430(6998):467-71 [15269772.001]

[Cites] J Neurosci. 2004 Sep 1;24(35):7604-13 [15342726.001]

[Cites] Anat Rec A Discov Mol Cell Evol Biol. 2004 Sep;280(1):924-31 [15382009.001]

[Cites] Brain Res. 1972 Jul 13;42(1):201-6 [5047187.001]

[Cites] Science. 1972 Aug 11;177(4048):532-3 [5050487.001]

[Cites] Br J Pharmacol. 1976 Mar;56(3):360P-361P [1260192.001]

[Cites] Brain Res. 1976 Aug 6;112(1):45-59 [947493.001]

[Cites] J Nutr. 1978 Feb;108(2):265-72 [413891.001]

[Cites] Endocrinology. 1981 Jul;109(1):70-5 [6263595.001]

[Cites] Brain Res. 1982 Aug 5;245(1):198-200 [6889453.001]

[Cites] Comp Biochem Physiol B. 1987;86(4):763-84 [3555984.001]

[Cites] Brain Res. 1990 Mar 12;511(1):158-62 [2331613.001]

[Cites] Neuroreport. 1995 Sep 11;6(13):1715-22 [8541467.001]

[Cites] J Neuroendocrinol. 1999 Aug;11(8):643-52 [10447803.001]

[Cites] Brain Res Mol Brain Res. 2004 Nov 4;130(1-2):109-14 [15519681.001]

[Cites] Cell. 2004 Nov 24;119(5):693-705 [15550250.001]

[Cites] BMC Mol Biol. 2004 Oct 9;5:18 [15473909.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):3111-6 [15710878.001]

[Cites] Nat Med. 2005 Mar;11(3):320-7 [15735652.001]

[Cites] Neuroscience. 2005;132(2):465-77 [15802197.001]

[Cites] Nature. 2005 Apr 21;434(7036):1026-31 [15846348.001]

[Cites] Cell Metab. 2005 Jan;1(1):53-61 [16054044.001]

[Cites] Brain Res Mol Brain Res. 2005 Oct 3;139(2):333-40 [16024134.001]

[Cites] Cell Metab. 2005 Nov;2(5):278-81 [16271527.001]

[Cites] Cell Metab. 2005 Nov;2(5):297-307 [16271530.001]

[Cites] Eur J Neurosci. 2005 Nov;22(10):2531-40 [16307595.001]

[Cites] Endocrine. 2005 Dec;28(3):325-32 [16388123.001]

[Cites] Cancer Causes Control. 2006 May;17(4):525-30 [16596306.001]

[Cites] Cell. 2006 May 5;125(3):497-508 [16678094.001]

(PMID = 19478857.001).

[ISSN] 1932-6203

[Journal-full-title] PloS one

[ISO-abbreviation] PLoS ONE

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Hormones

[Other-IDs] NLM/ PMC2682563

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

CONTEXT: Adrenal incidentalomas are common findings necessitating extensive laboratory work-up and repetitive radiological examinations.

OBJECTIVE: We evaluated 212 MTO-PET examinations in 173 patients to identify its role in the management of adrenal tumors.

PATIENTS: Patients who were operated or biopsied due to adrenal tumors had histopathological diagnoses of adrenocortical adenoma (n = 26), adrenocortical cancer (ACC; n = 13), adrenocortical hyperplasia (n = 8), pheochromocytoma (n = 6), metastasis (n = 3), and tumors of nonadrenal origin (n = 19).

The hypothesis that MTO-PET is of value in the management of adrenal tumors, especially incidentaloma, was stated before data collection.

Pheochromocytomas, metastases to the adrenal gland, and nonadrenal masses were all MTO negative.

SUV was higher in aldosterone-hypersecreting adenomas, and the SUV ratio between the tumor and the contralateral gland was significantly higher in all hormonally hypersecreting adenomas as well as in ACC.

MTO-PET is useful in the imaging work-up of adrenal incidentalomas and may be beneficial for the examination of patients with primary aldosteronism or ACC.

[MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenal Cortex Neoplasms / radionuclide imaging. Antineoplastic Agents. Etomidate / analogs & derivatives

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16403816.001).

[ISSN] 0021-972X

[Journal-full-title] The Journal of clinical endocrinology and metabolism

[ISO-abbreviation] J. Clin. Endocrinol. Metab.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 5377-20-8 / metomidate; Z22628B598 / Etomidate

   

Advertisement

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A case of polymyositis associated with adrenal carcinoma.

The association between idiopathic inflammatory myositis and cancer is well recognized.

Most descriptions have been of dermatomyositis-associated cancer, however, a few have been of polymyositis-associated adrenal cancer.

Here, we report a 69-year-old man in whom polymyositis-associated adrenal cancer was diagnosed.

Imaging studies showed a solid tumor measuring 14 x 9 cm in the retroperitoneum.

After surgical excision of the tumor, including the left kidney, the serum levels of creatine kinase and lactic dehydrogenase normalized, and symptoms of myositis disappeared.

[MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Carcinoma / diagnosis. Polymyositis / diagnosis

Genetic Alliance. consumer health - Polymyositis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17880299.001).

[ISSN] 0919-8172

[Journal-full-title] International journal of urology : official journal of the Japanese Urological Association

[ISO-abbreviation] Int. J. Urol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Australia

[Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 2.7.3.2 / Creatine Kinase

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Arc and resistance welding and tumours of the endocrine glands: a Swedish case-control study with focus on extremely low frequency magnetic fields.

AIMS: To analyse occupational exposure to ELF magnetic fields from welding, and tumours of the endocrine glands.

A total of 174 incident cases of tumours of the endocrine glands, 1985-94, were identified and data were obtained from 140 (80%) of these cases; 1692 controls frequency matched on sex and age were selected, and information on 1306 (77%) individuals was obtained.

RESULTS: There was an overall increased risk for all tumours of the endocrine glands for individuals who had been welding sometime during the follow up.

We found an increased risk for the adrenal glands in relation to arc welding, and for the parathyroid glands in relation to both arc welding and resistance welding.

An imprecise increase in risk was also noted for tumours of the pituitary gland for arc welding.

CONCLUSION: The increased risks of endocrine gland tumours related to welding might be explained by exposure to high levels of ELF magnetic fields.

[MeSH-major] Endocrine Gland Neoplasms / etiology. Magnetics / adverse effects. Occupational Diseases / etiology. Occupational Exposure / adverse effects. Welding

[MeSH-minor] Adrenal Gland Neoplasms / epidemiology. Adrenal Gland Neoplasms / etiology. Air Pollutants, Occupational / toxicity. Case-Control Studies. Cohort Studies. Female. Humans. Male. Parathyroid Neoplasms / epidemiology. Parathyroid Neoplasms / etiology. Pituitary Neoplasms / epidemiology. Pituitary Neoplasms / etiology. Risk Factors. Solvents / toxicity. Sweden / epidemiology. Time Factors

MedlinePlus Health Information. consumer health - Occupational Health.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Epidemiology. 2000 Jan;11(1):24-9 [10615839.001]

[Cites] Am J Epidemiol. 1999 Jul 1;150(1):27-36 [10400550.001]

[Cites] Endocr Relat Cancer. 2000 Mar;7(1):29-36 [10808194.001]

[Cites] Ann Epidemiol. 2001 Jul;11(5):297-303 [11399443.001]

[Cites] J Endocrinol Invest. 2001 Jun;24(6):454-9 [11434671.001]

[Cites] Neuroimmunomodulation. 2001;9(2):65-77 [11549888.001]

[Cites] Occup Environ Med. 2002 Jul;59(7):481-6 [12107298.001]

[Cites] Endocr Rev. 2003 Feb;24(1):1-27 [12588805.001]

[Cites] Breast Cancer. 2003;10(2):163-6 [12736571.001]

[Cites] Epidemiology. 2003 Jul;14(4):420-6; discussion 427-8 [12843765.001]

[Cites] Front Horm Res. 2004;32:63-95 [15281340.001]

[Cites] Am J Epidemiol. 1987 Apr;125(4):556-61 [3548332.001]

[Cites] Health Phys. 1989 Mar;56(3):297-302 [2917858.001]

[Cites] Lancet. 1991 Mar 23;337(8743):737 [1672204.001]

[Cites] Am J Epidemiol. 1991 Aug 15;134(4):340-7 [1877594.001]

[Cites] Am J Epidemiol. 1992 Jul 1;136(1):81-8 [1415133.001]

[Cites] Cancer Causes Control. 1994 Mar;5(2):189-94 [8167266.001]

[Cites] J Natl Cancer Inst. 1994 Jun 15;86(12):921-5 [8196082.001]

[Cites] Epidemiology. 1996 Sep;7(5):459-64 [8862974.001]

[Cites] Am Ind Hyg Assoc J. 1997 Jan;58(1):33-8 [9018835.001]

[Cites] J Surg Oncol. 1997 Jan;64(1):74-8 [9040805.001]

[Cites] Bioelectromagnetics. 1997;18(7):470-7 [9338628.001]

[Cites] Mol Carcinog. 1998 Mar;21(3):149-55 [9537645.001]

[Cites] Scand J Work Environ Health. 1998 Jun;24(3):183-9 [9710370.001]

[Cites] J Occup Environ Med. 2000 Feb;42(2):136-42 [10693073.001]

(PMID = 15837851.001).

[ISSN] 1470-7926

[Journal-full-title] Occupational and environmental medicine

[ISO-abbreviation] Occup Environ Med

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Air Pollutants, Occupational; 0 / Solvents

[Other-IDs] NLM/ PMC1741017

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Approach to the patient with an adrenal incidentaloma.

Unsuspected adrenal masses, or incidentalomas, are increasingly found with the widespread use of thoracic and abdominal imaging.

These masses may be hormonally active or nonfunctional and malignant or benign.

This is particularly important before surgical resection, which is routinely recommended for masses larger than 4 cm in diameter without a clear-cut diagnosis and for others with hormonal secretion or ominous imaging characteristics.

[MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / therapy. Algorithms. Carcinoma / diagnosis. Carcinoma / therapy. Incidental Findings

[MeSH-minor] Biopsy, Fine-Needle. Cushing Syndrome / complications. Cushing Syndrome / diagnosis. Diagnosis, Differential. Female. Humans. Middle Aged. Practice Guidelines as Topic

MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):637-44 [10690869.001]

[Cites] Endocr Pract. 2010 Jul-Aug;16(4):577-87 [20150023.001]

[Cites] J Clin Endocrinol Metab. 2000 Apr;85(4):1440-8 [10770179.001]

[Cites] Radiology. 2000 Dec;217(3):798-802 [11110946.001]

[Cites] Clin Endocrinol (Oxf). 2001 Jun;54(6):797-804 [11422115.001]

[Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5301-6 [11701696.001]

[Cites] J Intern Med. 2002 Sep;252(3):239-46 [12270004.001]

[Cites] Ann Intern Med. 2003 Mar 4;138(5):424-9 [12614096.001]

[Cites] Endocr J. 2003 Aug;50(4):399-408 [14599113.001]

[Cites] AJR Am J Roentgenol. 1979 Feb;132(2):231-8 [105590.001]

[Cites] Surgery. 1991 Dec;110(6):1014-21 [1745970.001]

[Cites] J Clin Endocrinol Metab. 1992 Mar;74(3):685-9 [1311000.001]

[Cites] Endocr Rev. 1995 Aug;16(4):460-84 [8521790.001]

[Cites] Clin Endocrinol (Oxf). 1997 Jan;46(1):29-37 [9059555.001]

[Cites] J Endocrinol Invest. 1997 Feb;20(2):65-71 [9125485.001]

[Cites] Horm Res. 1997;47(4-6):284-9 [9167966.001]

[Cites] J Clin Endocrinol Metab. 1998 Jan;83(1):55-62 [9435416.001]

[Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):871-7 [15572420.001]

[Cites] Endocrinol Metab Clin North Am. 2005 Jun;34(2):423-39, x [15850851.001]

[Cites] Endocr J. 2005 Aug;52(4):463-9 [16127216.001]

[Cites] Korean J Intern Med. 2005 Dec;20(4):303-9 [16491828.001]

[Cites] Eur J Endocrinol. 2006 Mar;154(3):419-23 [16498055.001]

[Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1410-4 [16403816.001]

[Cites] J Endocrinol Invest. 2006 Apr;29(4):298-302 [16699294.001]

[Cites] World J Surg. 2006 Sep;30(9):1665-71 [16927063.001]

[Cites] Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):483-99 [16980207.001]

[Cites] Nat Clin Pract Endocrinol Metab. 2007 Feb;3(2):92-102 [17237836.001]

[Cites] N Engl J Med. 2007 Feb 8;356(6):601-10 [17287480.001]

[Cites] Arch Esp Urol. 2007 Mar;60(2):217-21 [17484497.001]

[Cites] Endocr Relat Cancer. 2007 Sep;14(3):587-99 [17914090.001]

[Cites] Surgery. 2007 Oct;142(4):497-502; discussion 502-4 [17950341.001]

[Cites] Surgery. 2007 Dec;142(6):900-5; discussion 905.e1 [18063074.001]

[Cites] Rev Endocr Metab Disord. 2007 Dec;8(4):309-20 [17914676.001]

[Cites] Endocr J. 2008 Mar;55(1):121-6 [18202529.001]

[Cites] J Clin Endocrinol Metab. 2008 May;93(5):1526-40 [18334580.001]

[Cites] Endocr J. 2008 Aug;55(4):737-45 [18506093.001]

[Cites] J Clin Endocrinol Metab. 2008 Sep;93(9):3266-81 [18552288.001]

[Cites] Radiology. 2008 Dec;249(3):756-75 [19011181.001]

[Cites] Eur J Endocrinol. 2009 Jan;160(1):87-92 [18835977.001]

[Cites] J Clin Endocrinol Metab. 2009 Feb;94(2):456-62 [19001518.001]

[Cites] Ann Surg. 2009 Mar;249(3):388-91 [19247023.001]

[Cites] Eur J Endocrinol. 2009 Apr;160(4):647-55 [19174533.001]

[Cites] Clin Endocrinol (Oxf). 2009 May;70(5):674-9 [19067718.001]

[Cites] Eur J Endocrinol. 2009 Aug;161(2):355-61 [19497985.001]

[Cites] BJU Int. 2009 Sep;104(6):847-50 [19389014.001]

[Cites] Eur J Endocrinol. 2009 Oct;161(4):513-27 [19439510.001]

[Cites] Eur J Endocrinol. 2010 Jan;162(1):91-9 [19797503.001]

[Cites] J Endocrinol Invest. 2010 Jan;33(1):32-6 [19542759.001]

[Cites] Endocrinol Metab Clin North Am. 2000 Mar;29(1):159-85, x [10732270.001]

(PMID = 20823463.001).

[ISSN] 1945-7197

[Journal-full-title] The Journal of clinical endocrinology and metabolism

[ISO-abbreviation] J. Clin. Endocrinol. Metab.

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Number-of-references] 50

[Other-IDs] NLM/ PMC2936073

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] An evidence-based, multidisciplinary approach to the clinical considerations, management, and surveillance of adrenal lesions in familial adenomatous polyposis: report of three cases.

Adrenal masses are commonly discovered incidentally in patients with familial adenomatous polyposis, and adrenal malignancies have been rarely reported.

Adrenal lesions often are detected unexpectedly and are thus becoming a common clinical problem in this population.

Adrenal lesions encompass a heterogeneous spectrum of pathologic entities, including primary adrenocortical and medullary tumors, benign or malignant lesions, hormonally active or inactive lesions, metastases, and infections.

When an adrenal mass is detected, the clinician needs to address two crucial questions:.

1) is the mass malignant?

This article presents three new cases of incidental adrenal lesions in familial adenomatous polyposis, reviews the medical literature for this setting, and provides an overview of the diagnostic clinical approach and management of the adrenal findings in familial adenomatous polyposis patients.

[MeSH-major] Adenoma / complications. Adenomatous Polyposis Coli / complications. Adrenal Gland Neoplasms / complications

Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).

Genetic Alliance. consumer health - Familial Polyposis.

MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17041748.001).

[ISSN] 0012-3706

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] United States

[Number-of-references] 64

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Renal cell carcinoma and the renal sinus.

Renal sinus fat invasion was incorporated as one of the parameters for pT stage definition of renal cell carcinoma (RCC) only in the latest 2002 American Joint Committee on Cancer/tumor-node-metastasis staging protocol.

The current pT3a subcategory (in addition to adrenal gland involvement) groups 2 modes of extrarenal extension by RCC, either by peripheral perinephric fat extension or by renal sinus fat invasion.

Recent prospective studies have shown that with more directed gross sampling and histologic evaluation, renal sinus invasion is actually more commonly diagnosed than previously reported, or when compared with retrospectively sampled RCC nephrectomy specimens.

These studies have demonstrated that renal sinus invasion is the principal pathway for extrarenal extension for clear cell RCC; the incidence of which is related to size (tumors greater than 4 cm more frequently involve the renal sinus).

More significantly, a recent retrospective study of pT3a clear cell RCC nephrectomy specimens showed that tumors invading the renal sinus fat portend a more aggressive outcome than tumors invading only the peripheral perinephric fat.

Clear cell RCCs invading the renal sinus are more likely to have higher nuclear grade, regional lymph node involvement and sarcomatoid transformation than tumors invading only the perinephric fat.

Given the importance of renal sinus invasion, sampling strategies for nephrectomy specimens should be modified to focus in this region as appropriate and pathologists should be familiar with the histologic criteria for staging renal sinus invasion.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentOn] J Urol. 2005 Oct;174(4 Pt 1):1218-21 [16145373.001]

[CommentOn] J Urol. 2005 Oct;174(4 Pt 1):1199-202; discussion 1202 [16145369.001]

(PMID = 17471114.001).

[ISSN] 1072-4109

[Journal-full-title] Advances in anatomic pathology

[ISO-abbreviation] Adv Anat Pathol

[Language] eng

[Publication-type] Comment; Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Adrenal incidentalomas in the laparoscopic era and the role of correct surgical indications: observations from 255 consecutive adrenalectomies in an Italian series.

We analyzed the results of a multi-centre trial that was performed to evaluate the effectiveness of imaging (computed tomography and magnetic resonance imaging) to obtain a correct preoperative diagnosis.

METHODS: We obtained our data from the results of a questionnaire that was distributed by mail or email in May 2005 to several surgical units operating in the Campania Region, Italy.

RESULTS: The distribution of pathologic findings demonstrates that the number of lesions caused by cancer discovered from a preoperative indication of incidentaloma has been even smaller (1/114, 0.8%) than the previous numbers reported in the literature.

Moreover, whereas most patients with adrenal cancer had lesions larger than 6 cm (7/8, 87.5%), the majority of patients with adrenal metastases had lesions 6 cm or smaller (10/12, 83.3%).

Adrenal malignancies when metastatic are often 6 cm or smaller.

If they are single and they originated from a non-small lung cancer, they must be removed.

The endocrine surgery unit remains the best setting to evaluate and treat adrenal gland surgical pathology.

[MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods

MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Surgery. 2000 Dec;128(6):973-82;discussion 982-3 [11114632.001]

[Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):637-44 [10690869.001]

[Cites] ANZ J Surg. 2002 Jul;72(7):463-6 [12123500.001]

[Cites] World J Surg. 2002 Aug;26(8):1043-7 [12045859.001]

[Cites] Curr Opin Oncol. 2003 Jan;15(1):84-90 [12490767.001]

[Cites] Ann Intern Med. 2003 Mar 4;138(5):424-9 [12614096.001]

[Cites] NIH Consens State Sci Statements. 2002 Feb 4-6;19(2):1-25 [14768652.001]

[Cites] Endocr Rev. 2004 Apr;25(2):309-40 [15082524.001]

[Cites] Surg Clin North Am. 2004 Jun;84(3):755-74 [15145233.001]

[Cites] Br J Surg. 2004 Oct;91(10):1259-74 [15376201.001]

[Cites] Surgery. 1991 Dec;110(6):1014-21 [1745970.001]

[Cites] N Engl J Med. 1992 Oct 1;327(14):1033 [1387700.001]

[Cites] J Am Coll Surg. 1998 Feb;186(2):141-8 [9482616.001]

[Cites] World J Surg. 1999 Apr;23(4):389-96 [10030863.001]

[Cites] Br J Surg. 1999 Mar;86(3):385-7 [10201784.001]

[Cites] Am J Surg. 1999 Jul;178(1):50-3; discussion 54 [10456703.001]

[Cites] J Surg Oncol. 2005 Mar 1;89(3):186-92 [15719374.001]

[Cites] World J Surg. 2004 Nov;28(11):1169-75 [15490057.001]

[Cites] Am J Surg. 2005 Apr;189(4):405-11 [15820450.001]

[Cites] Am J Surg. 2005 May;189(5):581-5; discussion 585-6 [15862500.001]

[Cites] J Endourol. 2005 Jun;19(5):537-40 [15989440.001]

[Cites] Ann Chir. 2005 Oct;130(9):547-52 [15993374.001]

[Cites] Anticancer Res. 2005 Nov-Dec;25(6C):4559-62 [16334141.001]

[Cites] Oncologist. 2007 Feb;12(2):168-74 [17296812.001]

[Cites] J Clin Oncol. 2008 Mar 1;26(7):1142-7 [18309950.001]

[Cites] Br J Surg. 2002 Jun;89(6):779-82 [12027991.001]

(PMID = 20011165.001).

[ISSN] 1488-2310

[Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie

[ISO-abbreviation] Can J Surg

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Multicenter Study

[Publication-country] Canada

[Other-IDs] NLM/ PMC2792399

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

This study examined influences of hereditary factors and differences in catecholamine production on tumour expression of NPY, as assessed by quantitative PCR, enzyme immunoassay and immunohistochemistry.

Phaeochromocytomas included hereditary adrenaline-producing tumours (adrenergic phenotype) in multiple endocrine neoplasia type 2 (MEN 2), predominantly noradrenaline-producing tumours (noradrenergic phenotype) in von Hippel-Lindau (VHL) syndrome, and other adrenergic and noradrenergic tumours where there was no clear hereditary syndrome.

[MeSH-major] Adrenal Gland Neoplasms / chemistry. Neuropeptide Y / analysis. Pheochromocytoma / chemistry. von Hippel-Lindau Disease / metabolism

[MeSH-minor] Adult. Aged. Analysis of Variance. Female. Humans. Immunohistochemistry. Linear Models. Male. Middle Aged. Multiple Endocrine Neoplasia Type 2a / chemistry. Phenylethanolamine N-Methyltransferase / analysis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

Genetic Alliance. consumer health - Von Hippel-Lindau syndrome.

MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

MedlinePlus Health Information. consumer health - Pheochromocytoma.

MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cell Tissue Res. 2005 Dec;322(3):443-53 [16047163.001]

[Cites] J Clin Endocrinol Metab. 2001 May;86(5):1999-2008 [11344198.001]

[Cites] J Clin Invest. 1995 Nov;96(5):2503-9 [7593641.001]

[Cites] J Biol Chem. 1994 Jun 3;269(22):15460-8 [8195188.001]

[Cites] Clin Chim Acta. 2004 Jul;345(1-2):43-7 [15193976.001]

[Cites] Ann N Y Acad Sci. 2002 Oct;971:497-505 [12438170.001]

[Cites] Clin Endocrinol (Oxf). 1987 Jan;26(1):75-84 [2879655.001]

[Cites] Endocr Pathol. 2002 Spring;13(1):17-27 [12114747.001]

[Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]

[Cites] Cancer Cell. 2005 Aug;8(2):155-67 [16098468.001]

[Cites] Endocr Relat Cancer. 2004 Dec;11(4):897-911 [15613462.001]

[Cites] Ann N Y Acad Sci. 2006 Aug;1073:94-103 [17102076.001]

[Cites] Ann N Y Acad Sci. 2002 Sep;970:1-10 [12381537.001]

[Cites] Eur J Endocrinol. 2005 Oct;153(4):551-63 [16189177.001]

[Cites] Cell Tissue Res. 1995 May;280(2):267-76 [7781024.001]

[Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4505-9 [16912137.001]

[Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3747-51 [15769989.001]

[Cites] J Neurosci. 1990 Sep;10(9):2886-96 [1975838.001]

[Cites] Regul Pept. 2000 Jan 29;86(1-3):95-102 [10672908.001]

[Cites] Cancer Res. 1989 Dec 15;49(24 Pt 1):7010-4 [2582442.001]

[Cites] Int J Mol Med. 2005 Jan;15(1):3-13 [15583821.001]

[Cites] J Urol. 1999 Sep;162(3 Pt 1):659-64 [10458336.001]

[Cites] Clin Chem. 2005 Apr;51(4):735-44 [15718487.001]

[Cites] J Neurochem. 2006 Dec;99(5):1435-44 [17064356.001]

[Cites] Clin Chem. 2001 Jun;47(6):1075-82 [11375294.001]

[Cites] J Clin Endocrinol Metab. 1989 Apr;68(4):808-13 [2466046.001]

[Cites] Brain Res Dev Brain Res. 2003 Aug 12;144(1):1-8 [12888213.001]

[Cites] Clin Sci (Lond). 2002 Dec;103(6):535-42 [12444905.001]

[Cites] Lancet. 1983 Sep 3;2(8349):540-2 [6136694.001]

[Cites] Regul Pept. 1986 Jan;13(2):169-82 [3513267.001]

(PMID = 17470513.001).

[ISSN] 0022-0795

[Journal-full-title] The Journal of endocrinology

[ISO-abbreviation] J. Endocrinol.

[Language] eng

[Grant] United States / Intramural NIH HHS / / Z99 CT999999; United States / Intramural NIH HHS / /

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural

[Publication-country] England

[Chemical-registry-number] 0 / Neuropeptide Y; 0 / RNA, Messenger; EC 2.1.1.28 / Phenylethanolamine N-Methyltransferase

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [The clinical characteristic of adrenal metastatic tumor].

OBJECTIVE: To analyze the clinical features of adrenal metastasis.

METHODS: From January 1993 to December 2004, 103 cases of adrenal metastasis were reviewed.

RESULTS: Lung and hepatocellular carcinoma were the most common primary tumor of adrenal metastatic tumor, which about 36.9% (38/103) and 42.7% (44/103) of all cases, followed by renal carcinoma 6.8% (7/103), colorectal carcinoma 4.9% (5/103), stomach carcinoma 3.9% (4/103), breast cancer 1.9% (2/103), unknown primary tumor 2.9% (3/103).

The mean diameter of adrenal metastasis was 3.9 cm.

The mean interval from detection of primary tumor to adrenal metastasis was 9.5 months.

And 79.6% (82/103) were detected as a part of multiorgan metastasis.

CONCLUSIONS: There is no particular presentation of clinic and imaging, diagnosis depending on history, follow-up and the pathological presentation of primary tumor.

When the primary tumor could be resected or be well controlled, and there is no other evidence of metastasis, adrenalectomy is recommended.

[MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / secondary

[MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / pathology. Combined Modality Therapy. Female. Humans. Liver Neoplasms / pathology. Lung Neoplasms / pathology. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17418043.001).

[ISSN] 0529-5815

[Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]

[ISO-abbreviation] Zhonghua Wai Ke Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Dehydroepiandrosterone (DHEA) and its sulfate metabolite (DHEAS) are the major androgens secreted by the human adrenal gland.

The decline in their production is the most characteristic age-related change in the adrenal cortex.

This process, known as 'adrenopause' may contribute to the increased incidence of atherosclerosis, cancer, or dementia in older people.

Whereas DHEA therapy seems to be effective in treating patients with adrenal insufficiency and systemic lupus erythematosus, clinical studies investigating the potential efficacy of DHEA therapy in multiple other disorders (Alzheimer disease, depression, cardiovascular disease, osteoporosis, sexual dysfunctions) have not provided consistent results.

[MeSH-major] Adrenal Glands / metabolism. Adrenarche / physiology. Aging / metabolism. Dehydroepiandrosterone / metabolism. Dehydroepiandrosterone / therapeutic use

[MeSH-minor] Adrenal Gland Diseases / drug therapy. Adrenal Gland Diseases / metabolism. Aged. Atherosclerosis / metabolism. Atherosclerosis / prevention & control. Cardiovascular System / metabolism. Dementia / metabolism. Dementia / prevention & control. Humans. Lupus Erythematosus, Systemic / drug therapy. Lupus Erythematosus, Systemic / metabolism. Receptors, Steroid / metabolism

MedlinePlus Health Information. consumer health - Seniors' Health.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18634257.001).

[ISSN] 1426-9686

[Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego

[ISO-abbreviation] Pol. Merkur. Lekarski

[Language] pol

[Publication-type] English Abstract; Journal Article; Review

[Publication-country] Poland

[Chemical-registry-number] 0 / Receptors, Steroid; 0 / dehydroepiandrosterone receptor; 459AG36T1B / Dehydroepiandrosterone

[Number-of-references] 38

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer.

We also found that the prolyl hydroxylase EglN3 acts downstream of c-Jun and is specifically required among the three EglN family members for apoptosis in this setting.

[MeSH-major] Adrenal Gland Neoplasms / enzymology. Adrenal Gland Neoplasms / genetics. Apoptosis. Pheochromocytoma / enzymology. Pheochromocytoma / genetics. Procollagen-Proline Dioxygenase / metabolism. Tumor Suppressor Proteins / genetics. Ubiquitin-Protein Ligases / genetics

[MeSH-minor] Basic Helix-Loop-Helix Transcription Factors. DNA-Binding Proteins / metabolism. Dioxygenases. Gene Expression Regulation, Neoplastic. Humans. Hypoxia-Inducible Factor-Proline Dioxygenases. Immediate-Early Proteins / metabolism. Mutation. Nerve Growth Factor / metabolism. Neurons / enzymology. Protein Kinase C / metabolism. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-jun / genetics. Proto-Oncogene Proteins c-jun / metabolism. Proto-Oncogene Proteins c-ret. Receptor Protein-Tyrosine Kinases / genetics. Signal Transduction. Succinate Dehydrogenase / metabolism. Sympathetic Nervous System / cytology. Sympathetic Nervous System / growth & development. Transcription Factors / metabolism. Von Hippel-Lindau Tumor Suppressor Protein

Genetic Alliance. consumer health - Pheochromocytoma.

MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

MedlinePlus Health Information. consumer health - Pheochromocytoma.

COS Scholar Universe. author profiles.

Nature Publishing Group. commentaries/discussion - Highlights from Nature Reviews Cancer .

Addgene Non-profit plasmid repository. clones/clone libraries - Get Article's Plasmids - Addgene (subscription/membership/fee required).

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

eagle-i research resources. PMID 16098468 (Special Collections) .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Cancer Cell. 2005 Aug;8(2):91-3 [16098460.001]

(PMID = 16098468.001).

[ISSN] 1535-6108

[Journal-full-title] Cancer cell

[ISO-abbreviation] Cancer Cell

[Language] eng

[Grant] United States / NIDDK NIH HHS / DK / R01 DK065969; United States / NINDS NIH HHS / NS / R01 NS034400

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / Immediate-Early Proteins; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-jun; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / endothelial PAS domain-containing protein 1; 9061-61-4 / Nerve Growth Factor; EC 1.13.11.- / Dioxygenases; EC 1.14.11.2 / EGLN1 protein, human; EC 1.14.11.2 / Procollagen-Proline Dioxygenase; EC 1.14.11.29 / EGLN3 protein, human; EC 1.14.11.29 / Hypoxia-Inducible Factor-Proline Dioxygenases; EC 1.3.99.1 / Succinate Dehydrogenase; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.11.13 / Protein Kinase C; EC 6.3.2.19 / Ubiquitin-Protein Ligases; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Adrenal carcinoma: 7 year disease free survival after complete primary tumor resection and repeated resection of local-regional and distant recurrences. Review after one case with poor initial life expectancy].

[Transliterated title] Carcinoma suprarrenal: supervivencia a 7 años libre de enfermedad tras resección completa del tumor primario y resecciones repetidas de recidivas locorregional y a distancia. Revisión a raiz de un caso con una pobre esperanza de vida inicial.

OBJECTIVES: We report the case of a female patient with adrenal carcinoma who had undergone surgery and presented with local-regional and distant recurrences, emphasizing the importance of the aggressive surgical treatment to achieve long-term survival which is unexpected sometimes.

METHODS/RESULTS: We report the case of a 29-year-old female patient who consulted for left flank pain, being diagnosed of an adrenal tumor by radiological tests; she underwent surgical excision of a left adrenal carcinoma (stage II).

Currently, the patient is alive and free of disease 7 years after diagnosis.

CONCLUSIONS: Adrenal cancer recurrences have been considered lethal in the short-term.

Nevertheless, an aggressive surgical approach of local recurrences and metastasic disease may significantly prolong patient's survival and, sometimes, leave the patient disease free several years after the diagnosis of the primary tumor.

[MeSH-major] Adrenal Gland Neoplasms / surgery. Carcinoma / surgery

MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15847268.001).

[ISSN] 0004-0614

[Journal-full-title] Archivos españoles de urología

[ISO-abbreviation] Arch. Esp. Urol.

[Language] spa

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Spain

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Lung cancer presenting with extreme leukocytosis.

[MeSH-major] Adrenal Gland Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / secondary. Leukocytosis / etiology. Lung Neoplasms / pathology. Paraneoplastic Syndromes / etiology

Genetic Alliance. consumer health - Lung Cancer.

MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

MedlinePlus Health Information. consumer health - Lung Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20414953.001).

[ISSN] 1107-0625

[Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology

[ISO-abbreviation] J BUON

[Language] eng

[Publication-type] Case Reports; Letter

[Publication-country] Greece

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Adrenocortical carcinoma is a rare neoplasm occurring with a frequency of 1-2 cases per million.

It is characterized by significant malignancy with mean survival of about 28 months, and in the presence of documented metastases survival is shorter up to 8 months.

This type of a tumor is slightly more frequent in women (58.6%) than in men (41.4%).

The tumor size is still the best single predictor of prognosis.

Histopathology specimen from biopsy or obtained during operation should be stained for Melan A, which can confirm the adrenal origin of the tumor.

We presented the case of functioning adrenocortical cancer in 37-year-old patient who at time of diagnosis had 12 cm in diameter tumor of the left adrenal gland and metastases to the liver and lung.

[MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Liver Neoplasms / secondary. Lung Neoplasms / secondary

Genetic Alliance. consumer health - Adrenocortical Carcinoma.

MedlinePlus Health Information. consumer health - Liver Cancer.

MedlinePlus Health Information. consumer health - Lung Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17966598.001).

[Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej

[ISO-abbreviation] Pol. Arch. Med. Wewn.

[Language] pol

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Poland

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Primary adrenal natural killer/T-cell nasal type lymphoma: first case report in adults.

We report the first case of a primary adrenal natural killer (NK)/T-cell nasal type lymphoma in adults.

The patient presented with an enlarging left adrenal mass and the initial concern was for adrenocortical carcinoma.

Rapid recurrence in the contralateral adrenal gland was treated with a single cycle of chemotherapy before he died due to infectious complications and progressive disease.

This case demonstrates the aggressive presentation of a novel subset of primary adrenal lymphoma that should be considered in the differential diagnosis of a rapidly enlarging adrenal mass.

[MeSH-major] Adrenal Gland Neoplasms / pathology. Killer Cells, Natural / pathology. Lymphocyte Subsets / pathology. Lymphoma, T-Cell / pathology

MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17094095.001).

[ISSN] 0361-8609

[Journal-full-title] American journal of hematology

[ISO-abbreviation] Am. J. Hematol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Epstein-Barr virus encoded RNA 1; 0 / RNA, Viral

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Consequences of adrenal venous sampling in primary hyperaldosteronism and predictors of unilateral adrenal disease.

BACKGROUND: In patients with primary hyperaldosteronism, distinguishing between unilateral and bilateral adrenal hypersecretion is critical in assessing treatment options.

Adrenal venous sampling (AVS) has been advocated by some to be the gold standard for localization of the responsible lesion, but there remains a lack of consensus for the criteria and the standardization of technique.

STUDY DESIGN: We performed a retrospective study of 114 patients with a biochemical diagnosis of primary hyperaldosteronism who all underwent CT scan and AVS before and after corticotropin (ACTH) stimulation.

Factors associated with AVS lateralization included a low renin value, high plasma aldosterone-to plasma-renin ratio, and adrenal mass > or = 3 cm on CT scan.

[MeSH-major] Adrenal Gland Diseases / blood. Adrenal Gland Diseases / diagnosis. Adrenal Glands / blood supply. Adrenal Glands / metabolism. Hyperaldosteronism / blood. Hyperaldosteronism / diagnosis

[MeSH-minor] Adrenal Gland Neoplasms / blood. Adrenal Gland Neoplasms / diagnosis. Adrenalectomy. Adrenocorticotropic Hormone. Adult. Aged. Aldosterone / blood. Biomarkers / blood. Female. Humans. Hydrocortisone / blood. Hyperplasia / diagnosis. Male. Middle Aged. Renin / blood. Retrospective Studies. Tomography, X-Ray Computed. Veins

Genetic Alliance. consumer health - Hyperaldosteronism.

MedlinePlus Health Information. consumer health - Adrenal Gland Disorders.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. HYDROCORTISONE .

Hazardous Substances Data Bank. Corticotropin .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright © 2010 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

[Cites] J Am Coll Cardiol. 2005 Apr 19;45(8):1243-8 [15837256.001]

[Cites] Surgery. 2004 Dec;136(6):1227-35 [15657580.001]

[Cites] J Vasc Interv Radiol. 2008 Jan;19(1):66-71 [18192469.001]

[Cites] Ann Surg. 2008 Mar;247(3):511-8 [18376197.001]

[Cites] J Clin Endocrinol Metab. 2008 Sep;93(9):3266-81 [18552288.001]

[Cites] Int Urol Nephrol. 2008;40(4):1035-43 [18696249.001]

[Cites] Ann Intern Med. 2009 Sep 1;151(5):329-37 [19721021.001]

[Cites] Surg Clin North Am. 2009 Oct;89(5):1241-53 [19836495.001]

[Cites] Hypertension. 2010 Mar;55(3):667-73 [20124107.001]

[Cites] Clin Endocrinol (Oxf). 2010 Oct;73(4):551-2 [20550540.001]

[Cites] Surgery. 2006 Dec;140(6):847-53; discussion 853-5 [17188130.001]

[Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4526-33 [11134103.001]

[Cites] J Clin Endocrinol Metab. 2001 Mar;86(3):1066-71 [11238487.001]

[Cites] Ann Intern Med. 2001 Aug 21;135(4):258-61 [11511140.001]

[Cites] Endocrinology. 2003 Jun;144(6):2208-13 [12746276.001]

[Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1045-50 [15001583.001]

[Cites] N Engl J Med. 1967 Nov 16;277(20):1050-6 [6059584.001]

[Cites] Radiology. 1996 Feb;198(2):309-12 [8596821.001]

[CommentIn] Chirurg. 2012 Feb;83(2):176-7 [22271059.001]

(PMID = 20800196.001).

[ISSN] 1879-1190

[Journal-full-title] Journal of the American College of Surgeons

[ISO-abbreviation] J. Am. Coll. Surg.

[Language] eng

[Grant] United States / Intramural NIH HHS / / Z99 CA999999; United States / Intramural NIH HHS / / ZIA HD000642-12

[Publication-type] Journal Article; Research Support, N.I.H., Intramural

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers; 4964P6T9RB / Aldosterone; 9002-60-2 / Adrenocorticotropic Hormone; EC 3.4.23.15 / Renin; WI4X0X7BPJ / Hydrocortisone

[Other-IDs] NLM/ NIHMS206381; NLM/ PMC2930893

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Regression of orthotopic neuroblastoma in mice by targeting the endothelial and tumor cell compartments.

The aim of this study was primarily to characterize tumor spread in an orthotopic, metastatic model for aggressive, MYCN-amplified neuroblastoma and secondarily to study the effects of daily administration of the chemotherapeutic agent CHS 828 on tumor angiogenesis, tumor growth, and spread.

METHODS: MYCN-amplified human neuroblastoma cells (IMR-32, 2 x 10(6)) were injected into the left adrenal gland in SCID mice through a flank incision.

Nine weeks later, a new laparotomy was performed to confirm tumor establishment and to estimate tumor volume.

Differences between groups in tumor volume were analyzed by Mann-Whitney U test and in metastatic spread using Fisher's exact test.

RESULTS: The orthotopic model resembled clinical neuroblastoma in respect to tumor site, growth and spread.

Treatment with CHS 828 resulted in tumor regression (p < 0.001) and reduction in viable tumor fraction (p < 0.001) and metastatic spread (p < 0.05) in correlation with reduced plasma levels of the putative tumor marker chromogranin A (p < 0.001).

These effects were due to increased tumor cell death and reduced angiogenesis.

CONCLUSION: The metastatic animal model in this study resembled clinical neuroblastoma and is therefore clinically relevant for examining new treatment strategies for this malignancy.

[MeSH-minor] Animals. Autopsy. Calgranulin A / blood. Cell Line, Tumor. Cyanides / toxicity. Fibroblasts / drug effects. Guanidines / toxicity. Humans. Liver Neoplasms / secondary. Mice. Mice, SCID. Neoplasm Metastasis. Neovascularization, Pathologic / metabolism. Remission Induction. Risk Factors. Xenograft Model Antitumor Assays

Genetic Alliance. consumer health - Neuroblastoma.

MedlinePlus Health Information. consumer health - Neuroblastoma.

COS Scholar Universe. author profiles.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2003 Apr 15;21(8):1592-601 [12697885.001]

[Cites] Angiogenesis. 2002;5(4):267-74 [12906318.001]

[Cites] Cancer Res. 2003 Aug 1;63(15):4342-6 [12907602.001]

[Cites] Biochem Biophys Res Commun. 2008 Mar 21;367(4):799-804 [18201551.001]

[Cites] Nat Rev Cancer. 2004 Jun;4(6):423-36 [15170445.001]

[Cites] J Nucl Med. 2004 Jul;45(7):1172-88 [15235064.001]

[Cites] Cancer Res. 1978 Nov;38(11 Pt 1):3751-7 [29704.001]

[Cites] J Clin Invest. 1990 May;85(5):1555-9 [2332506.001]

[Cites] Leukemia. 1990 Aug;4(8):567-71 [2388483.001]

[Cites] Cancer Res. 1991 Aug 15;51(16):4342-6 [1868458.001]

[Cites] Drug Metab Dispos. 1994 Nov-Dec;22(6):947-55 [7895614.001]

[Cites] Clin Invest Med. 1995 Feb;18(1):47-65 [7768066.001]

[Cites] Eur J Cancer. 1995;31A(4):586-90 [7576974.001]

[Cites] J Clin Oncol. 1996 Feb;14(2):405-14 [8636750.001]

[Cites] J Endocrinol. 1996 Nov;151(2):225-30 [8958782.001]

[Cites] J Pediatr Surg. 1998 Dec;33(12):1765-70 [9869047.001]

[Cites] Am J Pathol. 1999 Feb;154(2):395-403 [10027398.001]

[Cites] J Pediatr Hematol Oncol. 1999 May-Jun;21(3):181-9 [10363850.001]

[Cites] Gene Ther. 1999 Jun;6(6):1147-52 [10455418.001]

[Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]

[Cites] J Clin Oncol. 2005 Feb 10;23(5):939-52 [15557593.001]

[Cites] Eur J Cancer. 2005 Mar;41(5):702-7 [15763645.001]

[Cites] Pediatr Res. 2005 May;57(5 Pt 1):690-5 [15718357.001]

[Cites] Eur J Pharm Sci. 2005 May;25(1):163-73 [15854812.001]

[Cites] Bioorg Med Chem Lett. 2005 May 16;15(10):2491-4 [15863303.001]

[Cites] Neuroendocrinology. 2005;82(3-4):171-6 [16508338.001]

[Cites] Science. 2006 May 26;312(5777):1171-5 [16728631.001]

[Cites] Pediatr Res. 2006 Nov;60(5):576-81 [16988184.001]

[Cites] Clin Cancer Res. 2007 Jun 15;13(12):3499-506 [17575212.001]

[Cites] FASEB J. 2003 Apr;17(6):764-6 [12586745.001]

[Cites] Clin Cancer Res. 2002 Sep;8(9):2843-50 [12231525.001]

[Cites] Anticancer Drugs. 2002 Aug;13(7):735-42 [12187330.001]

[Cites] Pediatr Res. 2002 May;51(5):607-11 [11978885.001]

[Cites] Ann Oncol. 2001;12 Suppl 2:S69-72 [11762355.001]

[Cites] J Pharmacol Exp Ther. 2001 Dec;299(3):1140-7 [11714905.001]

[Cites] Anticancer Drugs. 2001 Nov;12(10):821-7 [11707649.001]

[Cites] Eur J Cancer. 2001 Jan;37(2):260-7 [11166155.001]

[Cites] Eur J Cancer. 2000 May;36(7):901-8 [10785596.001]

[Cites] J Clin Invest. 2000 Apr;105(8):R15-24 [10772661.001]

[Cites] Cancer Res. 1999 Nov 15;59(22):5751-7 [10582695.001]

[Cites] Anticancer Drugs. 2004 Jan;15(1):63-70 [15090745.001]

(PMID = 19284605.001).

[ISSN] 1479-5876

[Journal-full-title] Journal of translational medicine

[ISO-abbreviation] J Transl Med

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Calgranulin A; 0 / Cyanides; 0 / Guanidines; 0 / N-(6-chlorophenoxyhexyl)-N''-cyano-N''-4-pyridylguanidine

[Other-IDs] NLM/ PMC2667491

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Radioligand binding assays in the cortex revealed a significantly lower number of A(1)AR (maximal binding capacity, Bmax) in the cortex of p50-/- mice (151+/-62 fmol/mg protein) versus 479+/-181 fmol/mg protein in the F2 (N=5 per strain, P<0.05), but no change in the equilibrium dissociation constant.

Similar reductions in A1AR were measured in the hippocampus, brain stem and hypothalamus and in peripheral tissues, such as the adrenal gland, kidney and spleen.

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Mol Pharmacol. 1999 Nov;56(5):947-54 [10531399.001]

[Cites] Am J Physiol. 1975 Jun;228(6):1896-902 [168787.001]

[Cites] Neuroscience. 2001;104(3):731-9 [11440805.001]

[Cites] Clin Cancer Res. 2001 Nov;7(11):3423-9 [11705858.001]

[Cites] Pharmacol Rev. 2001 Dec;53(4):527-52 [11734617.001]

[Cites] J Biol Chem. 2002 Jun 7;277(23):20717-23 [11912207.001]

[Cites] Eur J Pharmacol. 2002 May 10;442(3):251-64 [12065079.001]

[Cites] J Neurosci. 2002 Oct 1;22(19):8466-75 [12351721.001]

[Cites] EMBO J. 2003 Oct 15;22(20):5530-9 [14532125.001]

[Cites] Neuropharmacology. 2003 Dec;45(8):1120-9 [14614955.001]

[Cites] Hear Res. 2004 Feb;188(1-2):47-56 [14759570.001]

[Cites] Cell. 2004 Aug 20;118(4):453-64 [15315758.001]

[Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]

[Cites] Exp Neurol. 1977 Jun;55(3 PT. 1):719-24 [858344.001]

[Cites] Neurosci Lett. 1983 Dec 23;43(1):49-54 [6142434.001]

[Cites] J Cereb Blood Flow Metab. 1986 Oct;6(5):522-8 [3760038.001]

[Cites] Neurosci Lett. 1987 Dec 29;83(3):287-92 [3441311.001]

[Cites] Trends Pharmacol Sci. 1988 Apr;9(4):130-4 [2907698.001]

[Cites] J Biol Chem. 1991 Sep 25;266(27):17778-83 [1917922.001]

[Cites] J Biol Chem. 1992 Apr 5;267(10):6451-4 [1551861.001]

[Cites] Annu Rev Physiol. 1992;54:211-25 [1373278.001]

[Cites] Mol Cell Biol. 1992 Oct;12(10):4412-21 [1406630.001]

[Cites] Trends Pharmacol Sci. 1992 Dec;13(12):439-45 [1293870.001]

[Cites] Cardiovasc Res. 1993 Jan;27(1):62-7 [8458033.001]

[Cites] J Neurosci Res. 1993 Aug 1;35(5):567-76 [8377226.001]

[Cites] Brain Res Mol Brain Res. 1993 Oct;20(1-2):137-46 [8255175.001]

[Cites] Mol Cell Biol. 1994 Jun;14(6):3981-92 [8196637.001]

[Cites] Proc Natl Acad Sci U S A. 1994 May 24;91(11):4864-66 [8197148.001]

[Cites] Cell. 1995 Jan 27;80(2):321-30 [7834752.001]

[Cites] Nature. 1995 Jul 13;376(6536):167-70 [7603567.001]

[Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9328-32 [7568127.001]

[Cites] Brain Res. 1995 Apr 24;677(2):193-203 [7552243.001]

[Cites] Mol Pharmacol. 1995 Dec;48(6):975-80 [8848013.001]

[Cites] Science. 1996 Nov 1;274(5288):787-9 [8864120.001]

[Cites] J Neurosci Methods. 1997 Feb;71(2):143-55 [9128149.001]

[Cites] Hear Res. 1997 Sep;111(1-2):143-52 [9307320.001]

[Cites] J Exp Med. 1998 Jan 19;187(2):147-59 [9432973.001]

[Cites] Mol Pharmacol. 1998 Apr;53(4):663-9 [9547356.001]

[Cites] J Virol. 1998 Jul;72(7):5654-60 [9621024.001]

[Cites] Pharmacol Rev. 1998 Sep;50(3):413-92 [9755289.001]

[Cites] J Neurosci. 1998 Dec 15;18(24):10356-65 [9852573.001]

[Cites] J Comp Neurol. 1999 Aug 23;411(2):301-16 [10404255.001]

[Cites] J Neurosci. 1999 Oct 15;19(20):8856-65 [10516305.001]

[Cites] Trends Neurosci. 2005 Jan;28(1):37-43 [15626495.001]

[Cites] J Biol Chem. 2005 Mar 18;280(11):9786-95 [15640523.001]

[Cites] Endocrinology. 2005 Nov;146(11):4994-5002 [16081638.001]

[Cites] J Pharmacol Exp Ther. 2006 Apr;317(1):1-10 [16322354.001]

[Cites] J Neurosci. 2006 Mar 29;26(13):3541-50 [16571762.001]

[Cites] J Neurochem. 2006 Oct;99(1):42-53 [16987234.001]

[Cites] J Biol Chem. 2004 Oct 8;279(41):43157-67 [15272017.001]

[Cites] J Biol Chem. 2001 Apr 13;276(15):11821-9 [11096106.001]

(PMID = 17350174.001).

[ISSN] 0306-4522

[Journal-full-title] Neuroscience

[ISO-abbreviation] Neuroscience

[Language] ENG

[Grant] United States / NCRR NIH HHS / RR / K26 RR017543; United States / NCRR NIH HHS / RR / RR017543-01; United States / NCRR NIH HHS / RR / K26 RR017543-01; United States / PHS HHS / / R01-7543

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Lipopolysaccharides; 0 / NF-kappa B p50 Subunit; 0 / RNA, Messenger; 0 / Receptor, Adenosine A1; 0 / Xanthines; 102146-07-6 / 1,3-dipropyl-8-cyclopentylxanthine; EC 3.6.1.- / GTP-Binding Proteins

[Other-IDs] NLM/ NIHMS23082; NLM/ PMC2034751

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

A method was developed to assess mitochondrial movement in the living cell that is dependent, in part, on microtubule and/or associating protein interactions.

[MeSH-major] Adrenal Gland Neoplasms / metabolism. Antineoplastic Agents, Phytogenic / pharmacology. Mitochondria. Paclitaxel / pharmacology. Pheochromocytoma / metabolism

[MeSH-minor] Animals. Cell Line, Tumor. Fluorescent Dyes / metabolism. PC12 Cells / cytology. PC12 Cells / drug effects. PC12 Cells / physiology. Rats

MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

MedlinePlus Health Information. consumer health - Pheochromocytoma.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. TAXOL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Bioorg Med Chem. 2007 Jan 1;15(1):563-74 [17064914.001]

[Cites] Nature. 1978 Nov 23;276(5686):411-3 [714168.001]

[Cites] Proc Natl Acad Sci U S A. 1980 Mar;77(3):1561-5 [6103535.001]

[Cites] Scand J Immunol Suppl. 1982;9:299-316 [6763768.001]

[Cites] J Cell Biol. 1997 Dec 1;139(5):1137-55 [9382862.001]

[Cites] Eur J Cancer. 1997 Jun;33(7):1122-9 [9376193.001]

[Cites] Oncogene. 2003 Oct 20;22(47):7280-95 [14576838.001]

[Cites] Exp Neurol. 2008 Mar;210(1):229-37 [18078936.001]

[Cites] Nature. 1981 Dec 3;294(5840):477-80 [7312039.001]

[Cites] Gen Pharmacol. 1997 Aug;29(2):167-72 [9251895.001]

[Cites] Cancer Res. 2000 Oct 1;60(19):5349-53 [11034069.001]

[Cites] J Cell Biol. 2004 Oct 11;167(1):99-110 [15466480.001]

[Cites] Nat Rev Cancer. 2004 Apr;4(4):253-65 [15057285.001]

[Cites] Neurosci Res. 1999 Nov;35(2):113-22 [10616915.001]

[Cites] J Nat Prod. 1982 Jul-Aug;45(4):466-70 [7130988.001]

[Cites] J Cell Sci. 2001 Jan;114(Pt 2):281-91 [11148130.001]

[Cites] Annu Rev Cell Dev Biol. 1997;13:83-117 [9442869.001]

[Cites] Science. 2003 May 2;300(5620):808-12 [12730604.001]

[Cites] Int Rev Cytol. 1998;178:207-75 [9348671.001]

[Cites] Int J Dev Neurosci. 2004 Nov;22(7):453-65 [15465275.001]

[Cites] J Cell Sci. 1993 Mar;104 ( Pt 3):917-27 [8314882.001]

[Cites] Proc Natl Acad Sci U S A. 1976 Jul;73(7):2424-8 [1065897.001]

[Cites] Nat Rev Neurosci. 2005 Nov;6(11):889-98 [16224497.001]

[Cites] FEBS Lett. 1996 Sep 9;393(1):86-8 [8804430.001]

[Cites] Science. 1982 Dec 10;218(4577):1127-9 [6183744.001]

[Cites] J Neurocytol. 1984 Oct;13(5):685-701 [6150968.001]

[Cites] J Cell Biol. 1982 Sep;94(3):688-96 [6127342.001]

[Cites] Pain. 2006 Jun;122(3):245-57 [16530964.001]

[Cites] Curr Biol. 1995 Jun 1;5(6):635-42 [7552174.001]

[Cites] J Cell Biol. 1998 Nov 2;143(3):777-94 [9813097.001]

[Cites] J Biol Chem. 2002 Feb 22;277(8):6504-10 [11724773.001]

[Cites] Oncologist. 2008;13 Suppl 1:5-13 [18263769.001]

(PMID = 18636346.001).

[ISSN] 0895-8696

[Journal-full-title] Journal of molecular neuroscience : MN

[ISO-abbreviation] J. Mol. Neurosci.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Fluorescent Dyes; P88XT4IS4D / Paclitaxel

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pheochromocytomas and extra-adrenal paragangliomas detected by screening in patients with SDHD-associated head-and-neck paragangliomas.

Pheochromocytomas and extra-adrenal paragangliomas were treated surgically after appropriate blockade.

Twenty-eight out of the 93 patients were included in our study and underwent additional imaging for pheochromocytomas/extra-adrenal paragangliomas.

In 11 out of the 28 patients intra-adrenal pheochromocytomas were found.

Extra-adrenal paragangliomas were discovered in eight patients.

The high prevalence of pheochromocytomas/extra-adrenal paragangliomas in patients with SDHD-associated HNP warrants regular screening for tumors in these patients.

[MeSH-major] Adrenal Gland Neoplasms / diagnosis. Head and Neck Neoplasms / genetics. Paraganglioma, Extra-Adrenal / diagnosis. Pheochromocytoma / diagnosis. Succinate Dehydrogenase / genetics

MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

MedlinePlus Health Information. consumer health - Head and Neck Cancer.

MedlinePlus Health Information. consumer health - Pheochromocytoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19289533.001).

[ISSN] 1351-0088

[Journal-full-title] Endocrine-related cancer

[ISO-abbreviation] Endocr. Relat. Cancer

[Language] eng

[Publication-type] Clinical Trial; Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Catecholamines; EC 1.3.5.1 / SDHB protein, human; EC 1.3.99.1 / Succinate Dehydrogenase

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Von Hippel-Lindau (VHL) syndrome is a dominantly inherited familial cancer syndrome caused by mutations in the VHL gene.

Type 2 subtypes of VHL syndrome are characterized by the presence of pheochromocytoma and the three Type 2 subtypes are associated with differing risks of hemangioblastoma and renal cell carcinoma (RCC).

These results add to the growing body of evidence suggesting that patients with VHL syndrome caused by large VHL deletions that include C3orf10 may be designated as having a specific subtype (Type 1B) of the disorder.

[MeSH-major] Gene Deletion. Phenotype. Von Hippel-Lindau Tumor Suppressor Protein / genetics. von Hippel-Lindau Disease / classification

[MeSH-minor] Adrenal Gland Neoplasms / complications. Adrenal Gland Neoplasms / genetics. Carcinoma, Renal Cell / complications. Carcinoma, Renal Cell / genetics. Cerebellar Neoplasms / complications. Cerebellar Neoplasms / genetics. Cytoskeletal Proteins / genetics. DNA Mutational Analysis. Exons / genetics. Fanconi Anemia Complementation Group D2 Protein / genetics. Genotype. Germ-Line Mutation. Hemangioblastoma / complications. Hemangioblastoma / genetics. Humans. Kidney Neoplasms / complications. Kidney Neoplasms / genetics. Pheochromocytoma / complications. Pheochromocytoma / genetics. Retinal Neoplasms / complications. Retinal Neoplasms / genetics

MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19764026.001).

[ISSN] 1552-4833

[Journal-full-title] American journal of medical genetics. Part A

[ISO-abbreviation] Am. J. Med. Genet. A

[Language] eng

[Grant] United Kingdom / Cancer Research UK / /

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / BRK1 protein, human; 0 / Cytoskeletal Proteins; 0 / FANCD2 protein, human; 0 / Fanconi Anemia Complementation Group D2 Protein; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Here, we present a case of a false-positive (123)I-MIBG scan in a case of a mast-cell infiltrated infantile haemangioma and discuss the possible uptake mechanism.

[MeSH-major] 3-Iodobenzylguanidine / pharmacokinetics. Adrenal Gland Neoplasms / metabolism. Hemangioma / metabolism. Mast Cells / metabolism

MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

MedlinePlus Health Information. consumer health - Birthmarks.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Br J Cancer. 2003 Oct 6;89(7):1383-8 [14520475.001]

[Cites] Plast Reconstr Surg. 2004 Mar;113(3):999-1011 [15108898.001]

[Cites] J Histochem Cytochem. 2004 Jun;52(6):779-88 [15150286.001]

[Cites] Clin Nucl Med. 1991 Apr;16(4):239-42 [2044316.001]

[Cites] Acad Radiol. 2008 Aug;15(8):986-95 [18620119.001]

[Cites] Med Pediatr Oncol. 1997 Dec;29(6):589-92 [9324351.001]

[Cites] J Endocrinol Invest. 1998 Dec;21(11):779-83 [9972680.001]

[Cites] Pathologe. 2007 Jul;28(4):281-4 [16673076.001]

[Cites] Intern Med. 2007;46(20):1717-21 [17938527.001]

[Cites] Eur J Nucl Med. 1994 Jun;21(6):545-59 [8082671.001]

(PMID = 20675460.001).

[ISSN] 1748-880X

[Journal-full-title] The British journal of radiology

[ISO-abbreviation] Br J Radiol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Radiopharmaceuticals; 35MRW7B4AD / 3-Iodobenzylguanidine

[Other-IDs] NLM/ PMC3473506

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The human type 1 (placenta, breast tumors) and type 2 (gonads, adrenals) isoforms of 3beta-hydroxysteroid dehydrogenase/isomerase (3beta-HSD) are key enzymes in biosynthesis of all active steroid hormones.

Human 3beta-HSD1 is a critical enzyme in the conversion of DHEA to estradiol in breast tumors and may be a major target enzyme for the treatment of breast cancer.

3beta-HSD2 participates in the production of cortisol and aldosterone in the human adrenal gland.

Hazardous Substances Data Bank. TESTOSTERONE .

Hazardous Substances Data Bank. (L)-Methionine .

Hazardous Substances Data Bank. L-Threonine .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Biol Chem. 2002 Jul 12;277(28):25677-84 [11976334.001]

[Cites] J Steroid Biochem Mol Biol. 2007 Oct;107(1-2):80-7 [17624763.001]

[Cites] J Biol Chem. 2002 Nov 8;277(45):42795-801 [12205101.001]

[Cites] J Biol Chem. 2003 Sep 12;278(37):35483-90 [12832414.001]

[Cites] J Biol Chem. 2004 Apr 16;279(16):16778-85 [14966133.001]

[Cites] J Mol Endocrinol. 2004 Aug;33(1):253-61 [15291757.001]

[Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]

[Cites] J Med Chem. 1984 Jul;27(7):928-31 [6330362.001]

[Cites] J Steroid Biochem. 1988 Nov;31(5):785-93 [3199818.001]

[Cites] J Steroid Biochem. 1989 Aug;33(2):209-17 [2770297.001]

[Cites] Mol Endocrinol. 1991 Aug;5(8):1147-57 [1944309.001]

[Cites] Nucleic Acids Res. 1994 Nov 11;22(22):4673-80 [7984417.001]

[Cites] J Med Chem. 1995 Aug 18;38(17):3197-206 [7650672.001]

[Cites] Biochemistry. 1996 Feb 27;35(8):2557-66 [8611559.001]

[Cites] J Steroid Biochem Mol Biol. 1997 Apr;61(3-6):267-71 [9365200.001]

[Cites] Int J Cancer. 1997 Nov 27;73(5):735-9 [9398055.001]

[Cites] J Steroid Biochem Mol Biol. 1998 Sep;66(5-6):327-34 [9749838.001]

[Cites] Mol Endocrinol. 1999 Jan;13(1):66-81 [9892013.001]

[Cites] J Biol Chem. 2005 Jun 3;280(22):21321-8 [15797861.001]

[Cites] J Steroid Biochem Mol Biol. 2006 Sep;101(1):50-60 [16889958.001]

[Cites] Trends Endocrinol Metab. 2002 Aug;13(6):234-9 [12128283.001]

(PMID = 18524572.001).

[ISSN] 0960-0760

[Journal-full-title] The Journal of steroid biochemistry and molecular biology

[ISO-abbreviation] J. Steroid Biochem. Mol. Biol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA114717-21; United States / NCI NIH HHS / CA / R01 CA114717; United States / NCI NIH HHS / CA / CA114717; United States / NCI NIH HHS / CA / R01 CA114717-21

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] England

[Chemical-registry-number] 0 / Isoenzymes; 08J2K08A3Y / Dihydrotestosterone; 2ZD004190S / Threonine; 3XMK78S47O / Testosterone; AE28F7PNPL / Methionine; EC 1.1.- / 3-Hydroxysteroid Dehydrogenases; EC 5.3.3.- / Steroid Isomerases; L0FPV48Q5R / trilostane

[Other-IDs] NLM/ NIHMS65567; NLM/ PMC2580795

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Multiple endocrine neoplasia type I].

Multiple endocrine neoplasia type I (MEN1) is a rare hereditary cancer syndrome, which is manifested as a variety of endocrine and non-endocrine tumours and lesions caused by specific germline mutations of the MEN1 gene, a tumour suppressor gene.

The combined use of genetic and clinical tools for the diagnosis of MEN1-associated tumours substantially improves both the course of the disease and the quality of life of affected patients.

This review summarizes the relevant morphological and clinical features of MEN1-associated endocrine and non-endocrine neoplasms and lesions.

[MeSH-major] Multiple Endocrine Neoplasia Type 1 / pathology

[MeSH-minor] Adrenal Gland Neoplasms / genetics. Adrenal Gland Neoplasms / pathology. Carcinoma, Bronchogenic / genetics. Carcinoma, Bronchogenic / pathology. Germ-Line Mutation. Humans. Prevalence

Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Am J Gastroenterol. 2006 Feb;101(2):266-73 [16454829.001]

[Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):675-97 [16253893.001]

[Cites] Recent Prog Horm Res. 1999;54:397-438; discussion 438-9 [10548885.001]

[Cites] Gut. 2007 May;56(5):637-44 [17135306.001]

[Cites] Intern Med. 1996 Apr;35(4):285-9 [8739783.001]

[Cites] J Endocrinol Invest. 2007 Feb;30(2):145-9 [17392605.001]

[Cites] Genet Med. 2009 Dec;11(12):825-35 [19904212.001]

[Cites] Ann Surg. 2006 Feb;243(2):265-72 [16432361.001]

[Cites] Pathobiology. 2007;74(5):279-84 [17890894.001]

(PMID = 20960195.001).

[ISSN] 1432-1963

[Journal-full-title] Der Pathologe

[ISO-abbreviation] Pathologe

[Language] ger

[Publication-type] English Abstract; Journal Article; Review

[Publication-country] Germany

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Global and regional CpG methylation in pheochromocytomas and abdominal paragangliomas: association to malignant behavior.

PURPOSE: This study aims to quantitatively assess promoter and global methylation changes in pheochromocytomas and abdominal paragangliomas and its relation to tumor phenotypes.

EXPERIMENTAL DESIGN: A panel of 53 primary tumors (42 benign, 11 malignant) was analyzed by quantitative bisulfite pyrosequencing.

Based on methylation levels in the tumor suppressor genes, p16(INK4A), CDH1, DCR2, RARB, RASSF1A, NORE1A, TP73, APC, DAPK1, p14(ARF), and PTEN, a CpG island methylator phenotype (CIMP) was defined as concerted hypermethylation in three or more genes.

RESULTS: Five primary tumors (9.4%) exhibited a CIMP phenotype, four of which were malignant paragangliomas.

CIMP was significantly associated with malignant behavior (P = 0.005) and younger age at presentation (P < 0.007) but did not result from BRAF V600E mutation.

Global hypomethylation of LINE-1 elements was observed in tumors compared with normal adrenal samples (P < 0.02).

CONCLUSION: We here describe the identification of CIMP in abdominal paragangliomas and a strong association of this phenotype with malignant behavior, as well as young age at presentation.

[MeSH-major] Abdominal Neoplasms / genetics. Adrenal Gland Neoplasms / genetics. CpG Islands / genetics. DNA Methylation. Paraganglioma / genetics. Pheochromocytoma / genetics. Promoter Regions, Genetic

[MeSH-minor] Adolescent. Adult. Aged. Female. Genes, Tumor Suppressor. Humans. Long Interspersed Nucleotide Elements / genetics. Male. Middle Aged

MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

MedlinePlus Health Information. consumer health - Pheochromocytoma.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18451216.001).

[ISSN] 1078-0432

[Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research

[ISO-abbreviation] Clin. Cancer Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Melanoma adrenal metastasis: natural history and surgical management.

BACKGROUND: Few data exist regarding melanoma metastasis to the adrenal gland.

METHODS: A retrospective review of melanoma patients with adrenal metastasis was performed.

RESULTS: One hundred fifty-four patients with adrenal metastasis were identified.

CONCLUSIONS: Patients with melanoma adrenal metastasis have a poor prognosis.

Surgical treatment should be considered only in highly selected patients, such as those with limited extra-adrenal metastatic disease who can be rendered disease free.

[MeSH-major] Adrenal Gland Neoplasms / surgery. Melanoma / surgery. Skin Neoplasms / surgery

MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

MedlinePlus Health Information. consumer health - Melanoma.

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18206850.001).

[ISSN] 1879-1883

[Journal-full-title] American journal of surgery

[ISO-abbreviation] Am. J. Surg.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / P50 CA93459

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[MeSH-major] Adrenal Gland Neoplasms / genetics. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 3 / genetics. Pheochromocytoma / genetics

MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

MedlinePlus Health Information. consumer health - Pheochromocytoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17556075.001).

[ISSN] 0165-4608

[Journal-full-title] Cancer genetics and cytogenetics

[ISO-abbreviation] Cancer Genet. Cytogenet.

[Language] eng

[Publication-type] Comparative Study; Letter

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

At presentation, the tumor was confined to the liver in two patients and therefore surgically resected.

All five patients died from the tumor within 2 to 8 months.

The other three patients had metastatic choriocarcinoma in the lung (two patients), peritoneum (one patient), adrenal glands (one patient), and brain (one patient).

None of the patients had any evidence of a testicular tumor or scar after examination of the entirely submitted testes.

No tumor was observed in central nervous system, mediastinum, or other organs other than described above.

Immunohistochemically, tumor cells were strongly positive for keratin, HCG, and focally positive for human placental lactogen.

[MeSH-major] Choriocarcinoma / pathology. Liver Neoplasms / pathology

[MeSH-minor] Adrenal Gland Neoplasms / secondary. Adult. Brain Neoplasms / secondary. Chorionic Gonadotropin / blood. Humans. Ki-67 Antigen / analysis. Lung Neoplasms / secondary. Male. Middle Aged. Peritoneal Neoplasms / secondary. Placental Lactogen / analysis

Genetic Alliance. consumer health - Choriocarcinoma.

MedlinePlus Health Information. consumer health - Liver Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Thorac Cardiovasc Surg. 1985 Jun;89(6):826-35 [2987618.001]

[Cites] J Surg Oncol. 1987 Jan;34(1):39-42 [2433543.001]

[Cites] Prog Neurol Surg. 2009;23:59-75 [19329861.001]

[Cites] Am J Surg Pathol. 1997 Sep;21(9):1007-12 [9298876.001]

[Cites] Adv Anat Pathol. 2007 Mar;14(2):69-92 [17471115.001]

[Cites] Indian J Pathol Microbiol. 2003 Oct;46(4):658-9 [15025371.001]

[Cites] J Clin Pathol. 1998 Dec;51(12):939-40 [10070339.001]

[Cites] Acta Radiol Oncol. 1984;23(4):239-47 [6093440.001]

[Cites] Pathol Int. 2006 Jul;56(7):402-7 [16792550.001]

[Cites] Semin Diagn Pathol. 1990 Nov;7(4):266-84 [2178277.001]

[Cites] Virchows Arch. 1998 Jul;433(1):93-6 [9692832.001]

[Cites] Am J Surg Pathol. 2006 Jul;30(7):858-65 [16819328.001]

[Cites] Cancer. 1990 Jun 15;65(12):2681-5 [2160316.001]

[Cites] Hinyokika Kiyo. 2008 Apr;54(4):293-6 [18516924.001]

[Cites] Pediatr Radiol. 2004 Oct;34(10):820-3 [15378219.001]

[Cites] J Reprod Med. 2008 May;53(5):369-72 [18567286.001]

[Cites] Pediatr Pathol. 1993 Nov-Dec;13(6):723-30 [8108292.001]

[Cites] Cancer. 1993 Sep 15;72(6):1894-901 [7689921.001]

[Cites] J Postgrad Med. 1987 Oct;33(4):219-21 [3449627.001]

[Cites] Am J Med. 1971 Sep;51(3):416-22 [4940262.001]

[Cites] Hepatogastroenterology. 2001 Mar-Apr;48(38):424-6 [11379323.001]

[Cites] Transpl Int. 2008 Jun;21(6):598-601 [18363574.001]

[Cites] Int J Gynaecol Obstet. 2005 Feb;88(2):158-9 [15694099.001]

[Cites] Hum Pathol. 2004 Nov;35(11):1427-30 [15668903.001]

[Cites] Gastric Cancer. 2005;8(3):178-85 [16086121.001]

[Cites] Pediatr Blood Cancer. 2007 Jul;49(1):99-102 [16206190.001]

[Cites] Gastroenterol Clin Biol. 2007 Oct;31(10):854-7 [18166865.001]

[Cites] J Clin Oncol. 2004 May 1;22(9):1756-8 [15118001.001]

[Cites] Ann Diagn Pathol. 2009 Apr;13(2):96-100 [19302957.001]

[Cites] Pathol Res Pract. 1992 Apr;188(3):375-7; discussion 378-9 [1626001.001]

[Cites] J Urol. 2002 Apr;167(4):1789 [11912416.001]

[Cites] Br J Urol. 1983 Aug;55(4):440-4 [6883052.001]

[Cites] J Clin Oncol. 2008 Dec 10;26(35):5813-4 [19001337.001]

(PMID = 20013345.001).

[ISSN] 1432-2307

[Journal-full-title] Virchows Archiv : an international journal of pathology

[ISO-abbreviation] Virchows Arch.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / Ki-67 Antigen; 9035-54-5 / Placental Lactogen

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pheochromocytoma: advances in genetics, diagnosis, localization, and treatment.

Pheochromocytomas are rare, catecholamine-secreting tumors arising most frequently in the chromaffin cells of the adrenal glands.

Advances continue to be made not only in the genetic evaluation of these patients but also in the biochemical confirmation and tumor localization.

Surgery remains the definitive treatment, and advances in laparoscopic techniques as well as cortical-sparing procedures have reduced the morbidity associated with tumor resection.

[MeSH-major] Adrenal Gland Neoplasms. Pheochromocytoma

Genetic Alliance. consumer health - Pheochromocytoma.

MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

MedlinePlus Health Information. consumer health - Pheochromocytoma.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17548037.001).

[ISSN] 0889-8588

[Journal-full-title] Hematology/oncology clinics of North America

[ISO-abbreviation] Hematol. Oncol. Clin. North Am.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Catecholamines

[Number-of-references] 88

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Up to one third of all symptomatic presentations of pheochromocytoma or paraganglioma are due to germline mutations in one of six genes defining multiple endocrine neoplasia type 2, von Hippel-Lindau disease, neurofibromatosis type 1, and the paraganglioma syndromes types 1, 3, and 4.

This genetic classification forms the basis early diagnosis and follow-up including management of relatives.

Easily available clinical information such as tumor location and number, age, gender, and family history must be used to prioritize which gene should be tested.

Mutation carriers should undergo regular check-up to detect and treat metachronous paraganglial and extraparaganglial tumors, and depending on syndrome, other extraparaganglial neoplasias such as medullary thyroid cancer and renal clear cell carcinomas in time.

Adrenal and extraadrenal retroperitoneal tumors should be operated by surgeons highly experienced in minimal invasive, endoscopic techniques.

[MeSH-minor] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / genetics. Adrenal Gland Neoplasms / surgery. Adult. Genes, Neurofibromatosis 1. Germ-Line Mutation. Humans. Male. Multiple Endocrine Neoplasia Type 2a / genetics. Pheochromocytoma / diagnosis. Pheochromocytoma / genetics. Pheochromocytoma / surgery. Succinate Dehydrogenase / genetics. Terminology as Topic. Tomography, X-Ray Computed. Von Hippel-Lindau Tumor Suppressor Protein / genetics

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Neurol Neurosurg Psychiatry. 1999 Dec;67(6):758-62 [10567493.001]

[Cites] J Clin Endocrinol Metab. 2008 May;93(5):1573-5 [18463350.001]

[Cites] Nat Genet. 2000 Nov;26(3):268-70 [11062460.001]

[Cites] Am J Hum Genet. 2001 Jul;69(1):49-54 [11404820.001]

[Cites] Hypertension. 2001 Jul;38(1):6-8 [11463751.001]

[Cites] Radiology. 2002 Feb;222(2):507-12 [11818620.001]

[Cites] N Engl J Med. 2002 May 9;346(19):1459-66 [12000816.001]

[Cites] Nat Rev Cancer. 2003 Mar;3(3):193-202 [12612654.001]

[Cites] Lancet. 2003 Jun 14;361(9374):2059-67 [12814730.001]

[Cites] JAMA. 2004 Aug 25;292(8):943-51 [15328326.001]

[Cites] Lancet. 1989 Dec 2;2(8675):1291-4 [2574254.001]

[Cites] Br J Surg. 1999 Jan;86(1):94-7 [10027369.001]

[Cites] J Clin Endocrinol Metab. 1999 Aug;84(8):2608-10 [10443647.001]

[Cites] J Urol. 1999 Nov;162(5):1582-6 [10524872.001]

[Cites] JAMA. 2005 Oct 26;294(16):2057-63 [16249420.001]

[Cites] Cancer Res. 2005 Nov 1;65(21):9651-8 [16266984.001]

[Cites] J Clin Oncol. 2005 Dec 1;23(34):8812-8 [16314641.001]

[Cites] J Clin Endocrinol Metab. 2006 Mar;91(3):827-36 [16317055.001]

[Cites] World J Surg. 2006 May;30(5):899-908 [16617419.001]

[Cites] J Clin Endocrinol Metab. 2008 Dec;93(12):4818-25 [18826997.001]

[Cites] Clin Endocrinol (Oxf). 2009 Mar;70(3):354-7 [19067729.001]

[Cites] Cancer Res. 2009 Apr 15;69(8):3650-6 [19351833.001]

[Cites] J Clin Endocrinol Metab. 2009 May;94(5):1541-7 [19223516.001]

[Cites] J Clin Endocrinol Metab. 2009 May;94(5):1701-5 [19258401.001]

[Cites] N Engl J Med. 2006 Jun 22;354(25):2729-31 [16790714.001]

[Cites] Nat Clin Pract Endocrinol Metab. 2006 Feb;2(2):60-1 [16932255.001]

[Cites] J Clin Endocrinol Metab. 2006 Sep;91(9):3478-81 [16787982.001]

[Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4505-9 [16912137.001]

[Cites] Clin Endocrinol (Oxf). 2006 Dec;65(6):699-705 [17121518.001]

[Cites] Nat Rev Cancer. 2007 Jan;7(1):35-45 [17167516.001]

[Cites] J Clin Endocrinol Metab. 2007 Jul;92(7):2784-92 [17426081.001]

[Cites] J Med Genet. 2007 Sep;44(9):586-7 [17557926.001]

[Cites] N Engl J Med. 2007 Sep 27;357(13):1311-5 [17898100.001]

[Cites] J Clin Endocrinol Metab. 2007 Oct;92(10):3822-8 [17652212.001]

[Cites] Nat Clin Pract Endocrinol Metab. 2008 Feb;4(2):111-5 [18212813.001]

[Cites] J Clin Endocrinol Metab. 2008 May;93(5):1609-15 [18211978.001]

[Cites] Science. 2000 Feb 4;287(5454):848-51 [10657297.001]

(PMID = 19657044.001).

[ISSN] 1945-7197

[Journal-full-title] The Journal of clinical endocrinology and metabolism

[ISO-abbreviation] J. Clin. Endocrinol. Metab.

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / SDHD protein, human; EC 1.3.99.1 / Succinate Dehydrogenase; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein

[Other-IDs] NLM/ PMC2730863

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

A benign virilizing adrenal adenoma is rare among adrenal neoplasms in middle-aged women.

Abdominal computed tomography showed a left adrenal tumor, and an adrenocortical scintigraphy revealed uptake of the tracer on the left side.

Histopathological features of resected adrenal tumor were consistent with those of adrenocortical adenoma.

Immunoreactivity of all the steroidogenic enzymes was apparent in the tumor cells and particularly dehydroepiandrosterone sulfotransferase (DHEA-ST) immunoreactivity was markedly expressed.

Cortical atrophy and reduced expression of DHEA-ST were detected in the cortex of the adjacent non-neoplastic adrenal gland.

[MeSH-major] Adrenal Cortex Neoplasms / complications. Adrenalectomy. Adrenocortical Adenoma / complications. Cushing Syndrome / complications. Insulin Resistance. Polycystic Ovary Syndrome / therapy. Virilism / therapy

Genetic Alliance. consumer health - Cushing's Syndrome.

MedlinePlus Health Information. consumer health - Cushing's Syndrome.

MedlinePlus Health Information. consumer health - Polycystic Ovary Syndrome.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] J Endocrinol Invest. 2008 Apr;31(4):380-1 [18475059.001]

[Cites] J Clin Endocrinol Metab. 1986 Jan;62(1):16-21 [3940265.001]

[Cites] Ann Intern Med. 1983 Jun;98 (6):940-5 [6344711.001]

[Cites] Clin Endocrinol (Oxf). 2000 Oct;53(4):493-500 [11012575.001]

[Cites] J Clin Endocrinol Metab. 1993 May;76(5):1286-90 [8496319.001]

[Cites] Am J Med. 1963 Sep;35:374-83 [14065877.001]

[Cites] Clin Obstet Gynecol. 1990 Sep;33(3):640-54 [2225591.001]

[Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]

[Cites] Endocr J. 2003 Apr;50(2):179-87 [12803238.001]

[Cites] Endocr J. 1996 Aug;43(4):387-96 [8930526.001]

[Cites] Mod Pathol. 1995 Dec;8(9):891-6 [8751327.001]

[Cites] Trends Endocrinol Metab. 2004 Jul;15(5):204-10 [15223049.001]

[Cites] N Engl J Med. 1994 Oct 13;331(15):968-73 [8084355.001]

[Cites] Cancer. 1993 Sep 15;72(6):1997-2003 [8364880.001]

[Cites] Hum Reprod. 2004 Jan;19(1):41-7 [14688154.001]

[Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]

(PMID = 17318025.001).

[ISSN] 1720-8386

[Journal-full-title] Journal of endocrinological investigation

[ISO-abbreviation] J. Endocrinol. Invest.

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Italy

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

A sudden retroperitoneal hemorrhage may sometimes be the first symptom of the adrenal cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 23675071.001).

[ISSN] 1550-9702

[Journal-full-title] International journal of biomedical science : IJBS

[ISO-abbreviation] Int J Biomed Sci

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Other-IDs] NLM/ PMC3614665

[Keywords] NOTNLM ; adrenal cancer / retroperitoneal hemorrhage / steroids

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Gap junctions as modulators of adrenal cortical cell proliferation and steroidogenesis.

In the adrenal gland, as in most other tissues, intercellular communication provides the potential for regulation of a number of complex interactive cell processes including differentiation, steroidogenesis, migration, and proliferation.

This review is concerned with the regulation of gap junctions and cell function in cortical cells of the adrenal gland and in pathological disorders such as adrenal cancer.

[MeSH-major] Adrenal Cortex. Cell Proliferation. Gap Junctions / metabolism. Steroids / biosynthesis

[MeSH-minor] Adrenal Cortex Neoplasms / metabolism. Adrenal Cortex Neoplasms / physiopathology. Adrenal Medulla / cytology. Adrenal Medulla / physiology. Animals. Cell Movement / physiology. Connexins / metabolism

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18973789.001).

[ISSN] 0303-7207

[Journal-full-title] Molecular and cellular endocrinology

[ISO-abbreviation] Mol. Cell. Endocrinol.

[Language] eng

[Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Review

[Publication-country] Ireland

[Chemical-registry-number] 0 / Connexins; 0 / Steroids

[Number-of-references] 55

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

No evidence of recurrence in the intra- and extra hepatic organs such as adrenal gland, lung, bone, and brain except for intra abdominal solitary lymph node metastasis was observed.

[MeSH-major] Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / pathology. Liver Neoplasms / surgery. Lymphatic Metastasis / pathology

[MeSH-minor] Biomarkers, Tumor / blood. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Recurrence, Local. alpha-Fetoproteins / analysis

MedlinePlus Health Information. consumer health - Liver Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17212152.001).

[ISSN] 0385-0684

[Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy

[ISO-abbreviation] Gan To Kagaku Ryoho

[Language] jpn

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Robot-assisted excision of a retroperitoneal mass between the left renal artery and vein.

BACKGROUND: Extra-adrenal pheochromocytomas are rare.

METHODS: We present a case of a 64-year-old female with a 3.5-cm mass located between her left renal artery and vein, treated by a 4-port robot-assisted transperitoneal laparoscopic approach.

RESULTS: Careful dissection of the tumor away from the renal hilum was accomplished without major vascular injury.

A pedicle to the tumor was identified and ligated.

To our knowledge, this is the first report of a peri-hilar excision of a pheochromocytoma using this approach.

CONCLUSION: Extra-adrenal pheochromocytomas are rare and can present in difficult locations.

While surgical excision may be challenging, the da Vinci Robot may be used effectively and safely for the treatment of these perihilar masses.

MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

MedlinePlus Health Information. consumer health - Pheochromocytoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Endourol. 2007 Nov;21(11):1303-7 [18042019.001]

[Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):637-44 [10690869.001]

[Cites] Ann Intern Med. 2001 Feb 20;134(4):315-29 [11182843.001]

[Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5210-6 [11701678.001]

[Cites] J Natl Cancer Inst. 2003 Aug 20;95(16):1196-204 [12928344.001]

[Cites] Cancer Res. 2003 Sep 1;63(17):5615-21 [14500403.001]

[Cites] Endocr Rev. 2004 Apr;25(2):309-40 [15082524.001]

[Cites] Eur J Endocrinol. 2004 May;150(5):681-6 [15132724.001]

[Cites] JAMA. 2004 Aug 25;292(8):943-51 [15328326.001]

[Cites] J Urol. 1992 Jan;147(1):1-10 [1729490.001]

[Cites] Endocrinol Metab Clin North Am. 1994 Jun;23(2):387-404 [8070429.001]

[Cites] Med Clin North Am. 1995 Jan;79(1):131-53 [7808088.001]

[Cites] World J Surg. 1996 Sep;20(7):916-21; discussion 922 [8678971.001]

[Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2110-6 [15644401.001]

[Cites] Lancet. 2005 Aug 20-26;366(9486):665-75 [16112304.001]

(PMID = 21333207.001).

[ISSN] 1086-8089

[Journal-full-title] JSLS : Journal of the Society of Laparoendoscopic Surgeons

[ISO-abbreviation] JSLS

[Language] ENG

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Other-IDs] NLM/ PMC3041050

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Multiple endocrine neoplasia type 2 and the RET protooncogene: from bedside to bench to bedside.

Although the initial characterization of the various MEN-2 associated phenotypes (familial medullary thyroid cancer, multiple endocrine neoplasia 2A and 2B) evolved at the bedside, it was at the bench where the underlying RET (REarranged during Transfection) germline mutations were identified.

Molecular information has revolutionized our understanding and continues to transform the clinical management of this fascinating endocrine tumor syndrome of neural crest derivation, which consists of medullary thyroid cancer, pheochromocytoma, and parathyroid hyperplasia/adenoma.

With the continuing expansion of our knowledge about the underlying molecular mechanisms and our growing therapeutic abilities, multiple endocrine neoplasia type 2 is gradually returning home to the bedside, closing the loop from bedside to bench to bedside.

[MeSH-major] Multiple Endocrine Neoplasia Type 2a / genetics. Proto-Oncogene Proteins c-ret / genetics

[MeSH-minor] Adenoma / genetics. Adenoma / pathology. Adrenal Gland Neoplasms / genetics. Adrenal Gland Neoplasms / pathology. Adrenal Medulla / pathology. Age Factors. Animals. Carcinoma, Medullary / genetics. Carcinoma, Medullary / pathology. Genotype. Germ-Line Mutation. Humans. Hyperplasia. Multiple Endocrine Neoplasia Type 2b / genetics. Multiple Endocrine Neoplasia Type 2b / pathology. Neural Crest / pathology. Parathyroid Neoplasms / genetics. Parathyroid Neoplasms / pathology. Phenotype. Pheochromocytoma / genetics. Pheochromocytoma / pathology. Syndrome. Thyroid Neoplasms / genetics. Thyroid Neoplasms / pathology

Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.

Genetic Alliance. consumer health - Multiple endocrine neoplasia, type 2.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16343738.001).

[ISSN] 0303-7207

[Journal-full-title] Molecular and cellular endocrinology

[ISO-abbreviation] Mol. Cell. Endocrinol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Ireland

[Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-ret

[Number-of-references] 58

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD.

Succinate dehydrogenase B (SDHB) and D (SDHD) subunit gene mutations predispose to adrenal and extraadrenal pheochromocytomas, head and neck paragangliomas (HNPGL), and other tumor types.

We report tumor risks in 358 patients with SDHB (n=295) and SDHD (n=63) mutations.

Risks of malignant pheochromocytoma and renal tumors (14% at age 70 years) were higher in SDHB mutation carriers; 55 different mutations (including a novel recurrent exon 1 deletion) were identified.

Analysis of the largest cohort of SDHB/D mutation carriers has enhanced estimates of penetrance and tumor risk and supports in silicon protein structure prediction analysis for functional assessment of mutations.

[MeSH-major] Adrenal Gland Neoplasms / genetics. Germ-Line Mutation. Paraganglioma / genetics. Pheochromocytoma / genetics. Succinate Dehydrogenase / genetics

[MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. DNA Mutational Analysis. Female. Genetic Predisposition to Disease. Genotype. Head and Neck Neoplasms / genetics. Head and Neck Neoplasms / pathology. Humans. Male. Middle Aged. Phenotype. Young Adult

MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

MedlinePlus Health Information. consumer health - Pheochromocytoma.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Hum Mutat. 2010 Jun;31(6):761-2 [20513144.001]

(PMID = 19802898.001).

[ISSN] 1098-1004

[Journal-full-title] Human mutation

[ISO-abbreviation] Hum. Mutat.

[Language] eng

[Grant] United Kingdom / Department of Health / / DHCS/06/06/013

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / SDHD protein, human; EC 1.3.5.1 / SDHB protein, human; EC 1.3.99.1 / Succinate Dehydrogenase

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Radiographic evaluation of the incidental adrenal lesion.

The detection of incidental adrenal masses has increased substantially with the advent and widespread use of high-resolution cross-sectional imaging techniques such as CT and MRI.

The work-up and treatment of these incidentally found adrenal masses continue to be a clinical challenge for radiologists, endocrinologists, and adrenal surgeons.

The approach to the evaluation of most of these adrenal masses depends on the radiologic appearance of the lesion, and whether the patient has a known underlying malignancy.

The aim of this article is to review imaging features of pathologic abnormalities of the adrenal gland.

Recent advances in noninvasive imaging methods that attempt to differentiate benign from malignant lesions also are addressed.

[MeSH-major] Adrenal Gland Diseases / diagnosis

MedlinePlus Health Information. consumer health - Adrenal Gland Disorders.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Acta Med Scand. 1968 Sep;184(3):211-4 [5703975.001]

[Cites] J Comput Assist Tomogr. 1982 Oct;6(5):978-82 [7142516.001]

[Cites] Radiology. 1996 Nov;201(2):541-8 [8888255.001]

[Cites] J Urol. 1992 Jun;147(6):1478-81 [1593668.001]

[Cites] AJR Am J Roentgenol. 1996 Feb;166(2):395-400 [8553954.001]

[Cites] AJR Am J Roentgenol. 1995 Sep;165(3):579-83 [7645474.001]

[Cites] AJR Am J Roentgenol. 1996 Oct;167(4):861-7 [8819372.001]

[Cites] J Comput Assist Tomogr. 1982 Apr;6(2):281-5 [7076920.001]

[Cites] Radiology. 1996 Sep;200(3):743-7 [8756925.001]

[Cites] Semin Ultrasound CT MR. 1995 Aug;16(4):317-30 [7576778.001]

[Cites] J Magn Reson Imaging. 1995 Mar-Apr;5(2):171-4 [7766978.001]

[Cites] Radiology. 1995 Nov;197(2):411-8 [7480685.001]

[Cites] AJR Am J Roentgenol. 1983 Aug;141(2):303-5 [6603123.001]

[Cites] Radiology. 1997 Mar;202(3):693-6 [9051018.001]

[Cites] Radiology. 1997 Feb;202(2):517-21 [9015083.001]

[Cites] J Nucl Med. 1994 Jul;35(7):1145-52 [8014672.001]

[Cites] Radiology. 1992 Jul;184(1):1-13 [1609063.001]

[Cites] Radiol Clin North Am. 1996 Sep;34(5):1037-54 [8784395.001]

[Cites] J Urol. 1981 Sep;126(3):396-9 [7277608.001]

[Cites] AJR Am J Roentgenol. 1996 Mar;166(3):531-6 [8623622.001]

[Cites] Radiology. 1984 Mar;150(3):779-83 [6695079.001]

[Cites] Radiographics. 1997 Nov-Dec;17 (6):1373-85 [9397452.001]

[Cites] AJR Am J Roentgenol. 1990 May;154(5):927-36 [2108567.001]

[Cites] AJR Am J Roentgenol. 1987 Mar;148(3):531-5 [3492881.001]

[Cites] Radiology. 1991 May;179(2):415-8 [2014283.001]

[Cites] AJR Am J Roentgenol. 1998 Mar;170(3):747-52 [9490968.001]

[Cites] Cancer. 1950 Jan;3(1):74-85 [15405683.001]

(PMID = 16480675.001).

[ISSN] 1527-2737

[Journal-full-title] Current urology reports

[ISO-abbreviation] Curr Urol Rep

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 28

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinical management of large adrenal cystic lesions.

The widespread use of ultrasonography and computed tomography has resulted in an increased diagnosis of large sized adrenal cysts with diameters of more than 5 cm.

Most of these adrenal cystic lesions are clinically silent and are therefore often diagnosed incidentally.

Since up to 7% of adrenal cysts are malignant, a careful hormonal, morpho-functional and instrumental evaluation is mandatory.

In particular, functioning adrenal carcinomas or pheochromocytomas have to be ruled out.

Fine needle aspiration cytology as well as examination of a punch biopsy specimen of the cystic wall are of limited value, as there is considerable overlap in cytologic and histologic features of benign and malignant adrenal cystic lesions.

Immediate surgical excision is indicated in the presence of symptoms, suspicion of malignancy, increase in the size or detection of a functioning adrenal cyst.

[MeSH-major] Adrenal Gland Diseases / diagnosis. Cysts / diagnosis

[MeSH-minor] Adrenal Gland Neoplasms / diagnosis. Adrenalectomy. Female. Humans. Male. Middle Aged. Tomography, X-Ray Computed

MedlinePlus Health Information. consumer health - Adrenal Gland Disorders.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Arch Pathol Lab Med. 2000 Oct;124(10):1553-6 [11035597.001]

[Cites] AJR Am J Roentgenol. 1977 Jun;128(6):1013-6 [414531.001]

[Cites] J Chir (Paris). 1973 Nov;106(5):477-500 [4603323.001]

[Cites] World J Surg. 1996 Sep;20(7):769-74 [8678949.001]

[Cites] Surg Endosc. 2003 Feb;17(2):264-7 [12399875.001]

[Cites] World J Surg. 1996 Sep;20(7):788-92; discussion 792-3 [8678952.001]

[Cites] Anticancer Res. 2001 Mar-Apr;21(2B):1401-6 [11396222.001]

[Cites] ANZ J Surg. 2002 Jul;72(7):467-70 [12123501.001]

[Cites] Radiology. 1989 Oct;173(1):107-10 [2675177.001]

[Cites] J Endocrinol Invest. 1998 Feb;21(2):109-14 [9585385.001]

[Cites] N Engl J Med. 1990 Nov 15;323(20):1401-5 [2233907.001]

[Cites] Mayo Clin Proc. 2000 May;75(5):517-20 [10807082.001]

[Cites] Eur J Radiol. 2002 Feb;41(2):95-112 [11809539.001]

[Cites] J Cancer Res Clin Oncol. 2001;127(3):143-55 [11260859.001]

[Cites] Tex State J Med. 1951 Apr;47(4):234-7 [14835478.001]

[Cites] Int Urol Nephrol. 2000;32(2):227-9 [11229636.001]

[Cites] Br Med J. 1908 Jun 27;1(2478):1558-63 [20763927.001]

[Cites] J Urol. 1988 Jan;139(1):98-100 [3336114.001]

[Cites] J Nucl Med. 1994 Jul;35(7):1145-52 [8014672.001]

[Cites] Surgery. 1995 Dec;118(6):1071-5; discussion 1075-6 [7491525.001]

[Cites] Arch Surg. 1966 Jan;92(1):131-43 [5901251.001]

[Cites] Urol Clin North Am. 1977 Jun;4(2):273-83 [898414.001]

[Cites] AMA Arch Pathol. 1958 Jul;66(1):53-8 [13544691.001]

[Cites] Magn Reson Imaging Clin N Am. 1995 Feb;3(1):73-85 [7767747.001]

[Cites] Eur J Surg. 1991 Mar;157(3):237-8 [1678641.001]

[Cites] J Urol. 1965 Dec;94(6):635-8 [5843728.001]

[Cites] Am Surg. 1999 Feb;65(2):151-63 [9926751.001]

(PMID = 16362596.001).

[ISSN] 0301-1623

[Journal-full-title] International urology and nephrology

[ISO-abbreviation] Int Urol Nephrol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Netherlands

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Osteopontin (OPN), a multifunctional secreted phosphoglycoprotein, plays diverse roles in bone biology, immune regulation, cell survival, inflammation, and cancer metastasis.

[MeSH-major] Adrenal Cortex Hormones / biosynthesis. Hindlimb Suspension / physiology. Lymphatic System / pathology. Osteopontin / physiology. Weight Loss / physiology

[MeSH-minor] Animals. Anti-Inflammatory Agents / pharmacology. Apoptosis / drug effects. Atrophy. Cell Count. Corticosterone / blood. Cytokines / biosynthesis. Dexamethasone / pharmacology. Fluorescent Antibody Technique, Direct. Mice. Mice, Knockout. Spleen / cytology. Spleen / immunology. Spleen / physiology. T-Lymphocyte Subsets / cytology. T-Lymphocyte Subsets / metabolism. Thymus Gland / cytology. Thymus Gland / immunology. Thymus Gland / physiology

MedlinePlus Health Information. consumer health - Steroids.

MedlinePlus Health Information. consumer health - Weight Control.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. DEXAMETHASONE .

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Science. 2000 Feb 4;287(5454):860-4 [10657301.001]

[Cites] J Bone Miner Res. 2005 Feb;20(2):250-6 [15647819.001]

[Cites] J Exp Med. 2000 Apr 17;191(8):1423-8 [10770807.001]

[Cites] J Immunol. 2001 Jan 15;166(2):1079-86 [11145688.001]

[Cites] Int J Exp Pathol. 2000 Dec;81(6):373-90 [11298186.001]

[Cites] J Clin Invest. 2001 May;107(9):1055-61 [11342566.001]

[Cites] Science. 2001 Nov 23;294(5547):1731-5 [11721059.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4556-61 [11930008.001]

[Cites] Ann N Y Acad Sci. 2003 May;992:205-17 [12794060.001]

[Cites] Cytokine Growth Factor Rev. 2003 Dec;14(6):479-88 [14563350.001]

[Cites] Cell Res. 2003 Dec;13(6):465-71 [14728803.001]

[Cites] Immunity. 2004 Oct;21(4):539-50 [15485631.001]

[Cites] J Interferon Res. 1980 Fall;1(1):87-93 [6180049.001]

[Cites] Nature. 1989 Jun 22;339(6226):625-6 [2786609.001]

[Cites] J Biol Chem. 1994 Jan 7;269(1):711-5 [7506262.001]

[Cites] J Immunol. 1995 May 15;154(10):5511-27 [7730652.001]

[Cites] J Immunol. 1996 Apr 1;156(7):2608-15 [8786326.001]

[Cites] J Bone Miner Res. 1998 Jul;13(7):1101-11 [9661074.001]

[Cites] J Cell Biochem Suppl. 1998;30-31:92-102 [9893260.001]

[Cites] Neuroimmunomodulation. 2005;12(3):173-81 [15905626.001]

[Cites] Blood. 2005 Aug 1;106(3):946-55 [15855273.001]

[Cites] Int Immunol. 2005 Aug;17(8):1059-69 [16000327.001]

[Cites] Curr Pharm Biotechnol. 2005 Aug;6(4):343-9 [16101473.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17101-6 [16286640.001]

[Cites] J Mol Med (Berl). 2006 Apr;84(4):318-28 [16520944.001]

[Cites] J Dent Res. 2006 May;85(5):404-15 [16632752.001]

[Cites] J Immunol. 2006 Jun 1;176(11):6523-31 [16709809.001]

[Cites] Ann N Y Acad Sci. 2006 Jun;1069:62-76 [16855135.001]

[Cites] Exp Cell Res. 2006 Oct 1;312(16):3075-83 [16889770.001]

[Cites] J Cell Physiol. 2006 Sep;208(3):629-39 [16741956.001]

[Cites] Front Biosci. 2007;12:214-21 [17127294.001]

[Cites] Nat Immunol. 2007 Jan;8(1):74-83 [17143274.001]

[Cites] Endocrinology. 2007 Feb;148(2):575-84 [17110428.001]

[Cites] Neuroreport. 2007 Jan 22;18(2):153-7 [17301681.001]

[Cites] Neurobiol Dis. 2007 Mar;25(3):473-82 [17188882.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):1059-64 [9927693.001]

[Cites] Sports Med. 1999 Feb;27(2):73-80 [10091272.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):8156-60 [10393964.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2846-51 [10706626.001]

(PMID = 17785423.001).

[ISSN] 0027-8424

[Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America

[ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anti-Inflammatory Agents; 0 / Cytokines; 106441-73-0 / Osteopontin; 7S5I7G3JQL / Dexamethasone; W980KJ009P / Corticosterone

[Other-IDs] NLM/ PMC1976226